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ABSTRACT 
 
Localized drug delivery systems have been widely studied as potential replacements for 
conventional chemotherapy with the capability of providing sustained and controlled drug 
release in specific targeted sites. They offer numerous benefits over conventional chemotherapy 
such as enhancing the stability of embedded drugs and preserving their anticancer activity, 
providing sustained and controlled drug release in the tumor site, reducing toxicity and 
diminishing subsequent side effects, minimizing the drug loss, averting the need for frequent 
administrations, and minimizing the cost of therapy.  
The aim of this study is to develop a localized drug delivery system with niosomes 
embedded in a chitosan hydrogel with targeting capabilities. The incorporation of niosomes into 
a chitosan hydrogel has several advantages over each individually being used. First, embedding 
niosomes in a chitosan hydrogel can yield control over drug release especially for small molecule 
drugs. Second, chitosan hydrogel may improve the release time and dosage of drugs from 
niosomes by protecting them with an extra barrier, resulting in tunable release rates. Third, as a 
localized delivery system, chitosan hydrogels can prevent the migration of niosomes away from 
the targeted tumor sites.  Finally, chitosan has mucoadhesive property which can be used in the 
targeting of the tumor cells with the mucin over expression. 
To enhance the specific targeting, the capacity of chitosan to target MUC1 
overexpression in cancer cells will be analyzed. Similarly, the incorporation of chlorotoxin in 
this system will be achieved and evaluated. Chlorotoxin, a 36-amino acid peptide, is purified 
 ix 
 
from Leiurus quinquestriatus scorpion venom with a distinct characteristic of binding 
preferentially to neuroectoderma tumors such as glioma, but not to normal tissue. 
The overexpression of MUC1, a mucin antigen, in certain cancer cells has been used as 
an attractive therapeutic target in the design of a drug delivery system consisting of chitosan with 
a distinct mucoadhesive property. To determine the level of MUC1expression in different cell 
lines, Cell based Enzyme Linked Immunosorbent Assay (Cell ELISA) was developed for the 
first time.  
Attenuated Total Reflectance- Fourier Transform Infra-Red (ATR-FTIR) Spectroscopy is 
used to investigate the possible molecular interaction between chlorotoxin and glioma cells. This 
study presents a new approach in monitoring the biochemical and biophysical changes in glioma 
cells after being exposed to CTX. In addition to characterizing the signature spectra of CTX and 
glioma cells, we evaluated the differences in biochemical compositions of the spectra of the 
glioma cells treated with and without CTX over different incubation time periods. 
The results indicate that the proposed localized drug delivery system with the distinct 
tumor targeting features and extended release profiles would tune and control the specific 
delivery of chemotherapeutics in tumor sites.  
 1 
 
 
 
 
 
 
CHAPTER 1: INTRODUCTION 
 
According to American Cancer Society’s 2015 Cancer Statistics report, the lifetime 
probability of being diagnosed with an invasive cancer is slightly less than 1 in 2 for men and a 
little more than 1 in 3 for women, which leads to estimated 1,658,370 new cancer cases and 
589,430 cancer deaths in the United States in 2015 [1].   
Depending on the cancer type, diagnostic stage, and patient’s tolerance to different 
therapies, the treatment is then designed. Principal cancer treatment modalities include surgery, 
radiotherapy, and chemotherapy. Surgery is the first step in the treatment of solid tumors at early 
or intermediate stage in an accessible and localized region of the body [2]. Following tumor 
excision, conventional chemotherapy is applied to eradicate any remaining cancerous cells and to 
prevent tumor recurrence [2]. Despite of being the most common approach for cancer treatment, 
the efficacy of conventional chemotherapy is limited [2-4]. First, it distributes anticancer drugs to 
the whole body and does not differentiate between normal and cancer cells [3, 4]. In fact, only a 
small percentage of the administered drugs can reach the tumor areas leading to insufficient 
bioavailability of therapeutics in the sites needed treatment [3, 4]. 
Second, most of drug release occurs shortly after its administration causing the drug 
levels in the body to abruptly increase, peak and then decrease within a short period of time. This 
non-sustained drug release in conventional chemotherapy leads to undesirable side effects due to 
toxicities at the elevated drug levels and insufficient therapy afterwards [3-6]. 
 2 
 
Third, multiple injections are required to increase the bioavailability of drugs in the tumor 
sites. These repeated administrations can exacerbate the existing side effects such as kidney or 
nerve damage [2, 3, 5]. 
Finally, the need of using high amount of anticancer drugs in conventional chemotherapy, 
the need to treat inherent secondary effect and also the need for multiple cycles of chemo 
increase the cost of cancer treatment (Figure 1.1) [3, 5]. 
To overcome these problems, localized drug delivery systems have been widely studied 
as potential replacement for conventional chemotherapy with the capability of providing 
sustained and controlled drug release in specific targeted sites [3, 5, 6]. Localized drug delivery 
systems which are designed to enhance the efficacy of cancer treatments offer numerous benefits 
over conventional chemotherapy, and can be summarized as follows:  
1- Enhance the stability of embedded drugs and preserving their anticancer activity. 
2- Provide sustained and controlled drug release in the tumor site to ensure the adequate drug 
uptake into cancer cells. 
3- Reduce toxicity to the whole body and diminish of subsequent side effects by minimizing 
systemic distribution. 
4- Effective application of required therapeutics, and therefore, drug loss is minimal. 
5- Avert the need for frequent administrations.  
6- Minimize the cost of therapy as a result of requiring only one single administration.  
7- Tune the dosage and release of drugs 
Depending on the modality of administration and release mechanism, current local drug 
delivery systems can be categorized into two groups [3]. 
 3 
 
The first group consists of nanoparticles which are administered systematically with 
specific targeting property toward the tumor site [3-6]. Polymeric nanoparticles, polymeric 
micelles, dendrimers, liposomes, and niosomes are examples of these local drug delivery systems 
[3-7]. 
Also new therapeutic schemes based on the administration of living cells have been 
developed where the surface of therapeutic cells can be modified with artificial receptors, and 
multifunctional nanomaterials for enhanced cell therapies [8]. 
They can reach to the target sites by passive or active targeting. In passive targeting 
nanoparticles can diffuse through the leaky and dilated walls of tumor vasculature which results 
in their accumulation in the tumor site, while active targeting occurs due to interactions of 
ligands on nanoparticles with an over-expressed tumor cell marker (Figure 1.2) [9]. Despite the 
promising ability in targeting tumor sites, the localization of these nanoparticles is highly 
challenging as they are removed by the mononuclear phagocyte system (MPS) cells upon their 
intravenous administration (Figure 1.3) [10]. Blood monocytes, dendritic cells, and tissue-
resident macrophages are examples of the MPS cells which are responsible for detecting, 
clearing, and degrading foreign materials from circulation [10, 11]. In addition to reducing the 
bioavailability of drugs in the tumor sites, the MPS uptake of nanomaterials can cause other 
problems such as inflammation, toxicities due to the toxic byproducts, and distribution and 
accumulation of nanomaterials in sensitive body areas [10]. The uncontrolled and unpredicted 
localization of nanomaterials as well as the possibility of toxicity have hindered their translation 
into clinical applications [10, 12]. 
The second group consists of polymer based drug delivery systems with intratumoral or 
peritumoral injection, or implantation into tumor resection cavities. They have been designed in 
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various forms including gels, films, wafers, and rods, featuring controlled and sustained drug 
release kinetics. Implants require a surgical procedure at the tumor site, which leads to additional 
costs and complications.  
Thermoresponsive in-situ hydrogel systems have gained special attention in drug delivery 
[13]. Their initial liquid formulation can be applied at minimally invasive manner by a simple 
injection to fill the shape of any targeted area [14-16]. Upon their injection, they transform into a 
soft gel at body temperature (Figure 1.4). As mentioned above, synthetic polymers can be 
tailored and modified to provide excellent mechanical and chemical properties, but because of 
their synthetic origin, its application can lead to acute or chronic inflammations, retarded 
removal rates, and localized pH decrease as a result of the acidity of the accumulated degradation 
products [13]. 
Natural polymers such as polysaccharides and proteins are obtained from abundantly 
available natural resources with great biocompatibility and biodegradability properties. Unlike 
synthetic polymers, natural polymers can degrade into components which are non-inflammatory 
or cytotoxic [4]. 
Among them, polysaccharides have the advantage of interacting with living cells with 
excellent hemocompatibility. On the other hand, protein-originated polymers have the risk of 
immunegenecity and transmission of pathogens from animal donors [17]. 
Chitosan is a polysaccharide obtained by alkaline deacetylation of chitin [18]. It has been 
widely used in various biomedical applications, owing to its superior biocompatibility, 
enzymatic degradability and low toxicity [19, 20]. It also benefits from antimicrobial, antifungal 
actions and anticoagulant properties [4, 21]. 
 5 
 
Thermoresponsive chitosan hydrogel systems have been prepared with different chemical 
or physical crosslinking methods such as grafting polymerization of a polymer (e.g. poly(N-
isopropylacrylamide), poly(ethylene glycol) and Pluronic) onto chitosanor neutralization with 
polyol salts such as glycerol phosphate disodium salt [5, 17, 22-24]. 
Despite all the remarkable properties these hydrogels systems have some limitations [25]. 
Due to the high amount of water in the hydrogel network, the encapsulation of hydrophobic 
drugs is often challenging [25]. Also, large pores in their structure can lead to relatively fast 
release rates particularly for small molecule drugs [26]. 
To overcome these problems, incorporation of a secondary drug carrier such as 
liposomes, micelles, and other particle based vehicles into the hydrogel network has been 
considered recently [25-28]. 
Non-ionic surfactant vesicles or niosomes have been used as drug delivery vehicles [29-
33]. Similar to liposomes, niosomes have an enclosed spherical bilayer structure with hydrophilic 
core and hydrophobic shell allowing them to be used for encapsulating both hydrophilic and 
hydrophobic drugs [29]. Also, a mixture of hydrophobic and hydrophilic drugs can be 
encapsulated in the same vesicle [34]. As another advantage, niosomes do not interact with any 
of the charge groups of a drug molecule [29]. As compared to liposomes, niosomes provide 
better stability while having lower cost and being more convenient to store [29, 30]. 
In this study, niosomes with chemotherapeutic drugs are embedded in a thermoresponsive 
hydrogel network. Such configuration has allowed us to finely tune drug release time, 
concentration and dosage [35, 36]. 
The incorporation of niosomes into a chitosan hydrogel has several advantages over each 
individually being used. First, niosomes can encapsulate hydrophobic drugs which is challenging 
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in the case of embedding them in a pure hydrogel. Second, embedding niosomes in a chitosan 
hydrogel can yield slower drug release especially for small molecule drugs. Third, chitosan 
hydrogel may improve the release kinetics of drugs from niosomes by protecting them with an 
extra barrier and by preventing or decreasing the burst release, which is typical in spherical 
vesicles, resulting in extended release rates. Fourth, as a localized delivery system, chitosan 
hydrogels can prevent the migration of niosomes away from the targeted tumor sites. Finally, 
chitosan has mucoadhesive property which can be used in the targeting of the tumor cells with 
the mucin over expression.  
Therefore, developing a localized drug delivery system with niosomes embedded in 
chitosan hydrogel with enhanced targeting characteristics is the focus of this study. 
In targeted drug delivery a therapeutic agent is delivered specifically to a particular tumor 
cell [37]. Targeted drug delivery is highly beneficial in cancer therapy where anticancer drugs 
affect both tumor cells and normal cells resulting in toxicities and subsequent side effects [37]. 
Tumor-specific targeting therapy uses an approach where a tumor-specific molecule 
helps the drug to reach to the tumor cells [38]. This specific targeting is based on the interactions 
involved between the targeting molecules and the receptors present on the surface of tumor cells 
and not on the surface of normal cells [37]. 
Chlorotoxin (CTX) is a 36-amino acid peptide derived from the venom of the scorpion 
Leirius quinquestriatus that preferentially binds to tumor cells of neuroectodermal origin, such as 
glioma, but not to normal non-transformed cells [39-41]. Several studies have demonstrated its 
use as an imaging and targeting agent for drug and radioisotope delivery. 
Tumor paint BLZ-100, a bioconjugat of CTX and Cy5.5 (a near-infrared fluorescent 
molecule) has been recently approved to be tested in human clinical trials [42]. This bioconjugat 
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targets tumors with the fluorescent dye enabling surgeons to distinguish normal tissue from 
malignancies such as glioma, prostate cancer, intestinal cancer and sarcoma [42, 43]. CTX has 
been also investigated as a targeting agent in many drug delivery systems including CTX-
conjugated iron oxide nanoparticles and CTX-modified doxorubicine-loaded liposomes [44, 45]. 
To take advantage of this unique targeting feature, we have incorporated CTX along with 
niosomes in the chitosan hydrogel as the second targeting strategy to further improve the specific 
delivery of drugs to tumor cells such as glioma.  
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Figure 1.2 Schematic representation of an active targeting strategy to target tumor cells through 
the interactions of ligands on nanoparticles with an over-expressed tumor cell marker 
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Figure 1.3 Schematic representation of systematically administered Nanoparticles (NPs), 
showing their considerably higher uptake by the mononuclear phagocyte system (MPS) as 
compared to the tumor site 
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Figure 1.4 Chitosan/β-glycerophosphate in liquid form at room temperature (25°C) (a) and as a 
soft gel at body temperature (37°C) (b). 
 
  
 12 
 
1.1. References 
1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2015. CA: a cancer journal for 
clinicians, 2015. 65(1): p. 5-29. 
2. DeSantis, C.E., et al., Cancer treatment and survivorship statistics, 2014. CA: a cancer 
journal for clinicians, 2014. 64(4): p. 252-271. 
3. Wolinsky, J.B., Y.L. Colson, and M.W. Grinstaff, Local drug delivery strategies for 
cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. Journal of 
controlled release, 2012. 159(1): p. 14-26. 
4. De Souza, R., et al., Polymeric drug delivery systems for localized cancer chemotherapy. 
Drug delivery, 2010. 17(6): p. 365-375. 
5. Ta, H.T., C.R. Dass, and D.E. Dunstan, Injectable chitosan hydrogels for localised 
cancer therapy. Journal of Controlled Release, 2008. 126(3): p. 205-216. 
6. Cho, K., et al., Therapeutic nanoparticles for drug delivery in cancer. Clinical cancer 
research, 2008. 14(5): p. 1310-1316. 
7. Timko, B.P. and D.S. Kohane, Drug‐Delivery Systems for Tunable and Localized Drug 
Release. Israel Journal of Chemistry, 2013. 53(9‐10): p. 728-736. 
8. Stephan, M.T. and D.J. Irvine, Enhancing cell therapies from the outside in: cell surface 
engineering using synthetic nanomaterials. Nano today, 2011. 6(3): p. 309-325. 
9. Thassu, D., M. Deleers, and Y.V. Pathak, Nanoparticulate drug delivery systems. Vol. 
166. 2007: CRC Press. 
10. Walkey, C.D., et al., Nanoparticle size and surface chemistry determine serum protein 
adsorption and macrophage uptake. Journal of the American Chemical Society, 2012. 
134(4): p. 2139-2147. 
11. Moghimi, S.M., A.C. Hunter, and J.C. Murray, Long-circulating and target-specific 
nanoparticles: theory to practice. Pharmacological reviews, 2001. 53(2): p. 283-318. 
12. Davis, M.E. and D.M. Shin, Nanoparticle therapeutics: an emerging treatment modality 
for cancer. Nature reviews Drug discovery, 2008. 7(9): p. 771-782. 
13. Yu, L. and J. Ding, Injectable hydrogels as unique biomedical materials. Chemical 
Society Reviews, 2008. 37(8): p. 1473-1481. 
14. Kim, S., et al., A chitosan/β-glycerophosphate thermo-sensitive gel for the delivery of 
ellagic acid for the treatment of brain cancer. Biomaterials, 2010. 31(14): p. 4157-4166. 
15. Obara, K., et al., Photocrosslinkable chitosan hydrogel containing fibroblast growth 
factor-2 stimulates wound healing in healing-impaired db/db mice. Biomaterials, 2003. 
24(20): p. 3437-3444. 
16. Ruel-Gariépy, E., et al., A thermosensitive chitosan-based hydrogel for the local delivery 
of paclitaxel. European Journal of Pharmaceutics and Biopharmaceutics, 2004. 57(1): p. 
53-63. 
 13 
 
17. Bhattarai, N., J. Gunn, and M. Zhang, Chitosan-based hydrogels for controlled, localized 
drug delivery. Advanced drug delivery reviews, 2010. 62(1): p. 83-99. 
18. Kumar, M.N.R., A review of chitin and chitosan applications. Reactive and functional 
polymers, 2000. 46(1): p. 1-27. 
19. Chandy, T. and C.P. Sharma, Chitosan-as a biomaterial. Biomaterials, artificial cells and 
artificial organs, 1990. 18(1): p. 1-24. 
20. Kean, T. and M. Thanou, Biodegradation, biodistribution and toxicity of chitosan. 
Advanced drug delivery reviews, 2010. 62(1): p. 3-11. 
21. Ganji, F., M. Abdekhodaie, and A.R. SA, Gelation time and degradation rate of 
chitosan-based injectable hydrogel. Journal of sol-gel science and technology, 2007. 
42(1): p. 47-53. 
22. Park, K.M., et al., Thermosensitive chitosan–Pluronic hydrogel as an injectable cell 
delivery carrier for cartilage regeneration. Acta biomaterialia, 2009. 5(6): p. 1956-1965. 
23. Chenite, A., et al., Rheological characterisation of thermogelling chitosan/glycerol-
phosphate solutions. Carbohydrate Polymers, 2001. 46(1): p. 39-47. 
24. Ruel-Gariepy, E., et al., Thermosensitive chitosan-based hydrogel containing liposomes 
for the delivery of hydrophilic molecules. Journal of Controlled Release, 2002. 82(2): p. 
373-383. 
25. Hoare, T.R. and D.S. Kohane, Hydrogels in drug delivery: progress and challenges. 
Polymer, 2008. 49(8): p. 1993-2007. 
26. Pan, W. and Z. Yang, Thermoreversible Pluronic® F127-based hydrogel containing 
liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, 
and uptake studies. International journal of nanomedicine, 2011. 6: p. 151-166. 
27. Wang, C., N.T. Flynn, and R. Langer, Controlled structure and properties of 
thermoresponsive nanoparticle–hydrogel composites. Advanced Materials, 2004. 16(13): 
p. 1074-1079. 
28. Segovia, N., et al., Hydrogel doped with nanoparticles for local sustained release of 
siRNA in breast cancer. Advanced healthcare materials, 2015. 4(2): p. 271-280. 
29. Uchegbu, I.F. and S.P. Vyas, Non-ionic surfactant based vesicles (niosomes) in drug 
delivery. International Journal of pharmaceutics, 1998. 172(1): p. 33-70. 
30. Manosroi, A., et al., Characterization of vesicles prepared with various non-ionic 
surfactants mixed with cholesterol. Colloids and Surfaces B: Biointerfaces, 2003. 30(1): 
p. 129-138. 
31. Pardakhty, A., J. Varshosaz, and A. Rouholamini, In vitro study of polyoxyethylene alkyl 
ether niosomes for delivery of insulin. International journal of pharmaceutics, 2007. 
328(2): p. 130-141. 
32. Bayindir, Z.S. and N. Yuksel, Characterization of niosomes prepared with various 
nonionic surfactants for paclitaxel oral delivery. Journal of pharmaceutical sciences, 
2010. 99(4): p. 2049-2060. 
 14 
 
33. Pham, T.T., et al., Liposome and niosome preparation using a membrane contactor for 
scale-up. Colloids and Surfaces B: Biointerfaces, 2012. 94: p. 15-21. 
34. Williams, E.C., Smart Packaging: A Novel Technique For Localized Drug Delivery For 
Ovarian Cancer. 2012. 
35. Williams, E.C., R. Toomey, and N. Alcantar, Controlled release niosome embedded 
chitosan system: Effect of crosslink mesh dimensions on drug release. Journal of 
Biomedical Materials Research Part A, 2012. 100(12): p. 3296-3303. 
36. Falahat, R., et al., Targeted delivery to tumor cells by using tunable nano-delivery system 
with chlorotoxin. Cancer Research, 2013. 73(8 Supplement): p. 4523-4523. 
37. Brannon-Peppas, L. and J.O. Blanchette, Nanoparticle and targeted systems for cancer 
therapy. Advanced drug delivery reviews, 2004. 56(11): p. 1649-1659. 
38. Park, J.H., et al., Targeted delivery of low molecular drugs using chitosan and its 
derivatives. Advanced drug delivery reviews, 2010. 62(1): p. 28-41. 
39. Debin, J.A., J.E. Maggio, and G.R. Strichartz, Purification and characterization of 
chlorotoxin, a chloride channel ligand from the venom of the scorpion. American Journal 
of Physiology-Cell Physiology, 1993. 264(2): p. C361-C369. 
40. Lyons, S.A., J. O'Neal, and H. Sontheimer, Chlorotoxin, a scorpion‐derived peptide, 
specifically binds to gliomas and tumors of neuroectodermal origin. Glia, 2002. 39(2): p. 
162-173. 
41. Wiranowska, M., L.O. Colina, and J.O. Johnson, Clathrin-mediated entry and cellular 
localization of chlorotoxin in human glioma. Cancer Cell Int, 2011. 11: p. 27. 
42. Butte, P.V., et al., Near-infrared imaging of brain tumors using the Tumor Paint BLZ-
100 to achieve near-complete resection of brain tumors. Neurosurgical focus, 2014. 
36(2): p. E1. 
43. Veiseh, M., et al., Tumor paint: a chlorotoxin: Cy5. 5 bioconjugate for intraoperative 
visualization of cancer foci. Cancer research, 2007. 67(14): p. 6882-6888. 
44. Sun, C., et al., Tumor-targeted drug delivery and MRI contrast enhancement by 
chlorotoxin-conjugated iron oxide nanoparticles. 2008. 
45. Xiang, Y., et al., Chloride channel-mediated brain glioma targeting of chlorotoxin-
modified doxorubicine-loaded liposomes. Journal of controlled release, 2011. 152(3): p. 
402-410. 
  
 15 
 
 
 
 
 
 
CHAPTER 2: CHLOROTOXIN-MODIFIED NIOSOME-CHITOSAN HYDROGEL 
COMPLEXES FOR SUSTAINED, CONTROLLED AND TARGETED DRUG 
DELIVERY 
 
2.1. Abstract 
This study reports a development and characterization of a localized drug delivery system 
with enhanced targeting ability consisting of non-ionic surfactant vesicles (niosomes) with 
chlorotoxin (CTX) embedded in a chitosan hydrogel. With the controlled, sustained and targeted 
delivery features, this system represents a novel approach in cancer therapy. 
Release profiles of 5,6-carboxyfluorescein from niosomes alone, niosomes in chitosan 
hydrogel, and CTX-niosomes in chitosan hydrogel were studied in a release medium with low 
ionic strength and pH 6.0 (similar to tumor extracellular pH). Morphological assessments of 
niosomes alone and niosomes with CTX were performed using Transmission electron 
microscopy (TEM). Attenuated Total Reflectance-Fourier Transform Infra-Red (ATR-FTIR) 
spectroscopy was also employed to study the possible interactions between niosomes and CTX.  
Release rate studies indicated that embedding niosomes in chitosan hydrogel significantly 
extends the release rates after 24 h. Embedding CTX along with niosomes in chitosan hydrogel 
resulted in slightly more extended release rates as compared to the release rates from niosomes 
alone in chitosan hydrogel. Attachment of CTX to the surface of niosomes shown by TEM 
imaging improved the stability of niosomes resulting in extended release rates. ATR-FTIR 
studies also confirmed the interaction of CTX with niosomes.  
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2.2. Introduction 
Non-ionic surfactant vesicles (niosomes) are among the common vesicular systems 
widely studied as drug delivery vehicles [1-5]. Similar to liposomes, niosomes have an enclosed 
spherical bilayer structure with hydrophilic core and hydrophobic shell allowing them to be used 
for the delivery of both hydrophilic and hydrophobic drugs [6, 7]. Also, a mixture of 
hydrophobic and hydrophilic drugs can be encapsulated in the same vesicle [8]. Niosomes have 
been reported to provide better stability while having lower cost and being more convenient to 
store as compared to liposomes [1, 2]. Having these benefits, niosomes have received a great 
attention as potential delivery systems for various drugs and therapeutic agents such as 
anticancer drugs (doxorubicin, paclitaxel and carboplatin) [8-10], insulin [3, 11], vasoactive 
intestinal peptide (VIP) [12], and many others.  
Despite all the promising features, the localization of niosomes in tumor sites is highly 
challenging due to their removal by the mononuclear phagocyte system (MPS) cells upon the 
systemic administration [13]. Also, as being osmotically active they may have an undesired burst 
release which is typical in spherical vesicles.  
To overcome these problems, in this study niosomes were embedded in a thermosensitive 
chitosan hydrogel network. The initial liquid formulation of chitosan hydrogel at room 
temperature allows it to be injected into the cavities after tumor resection and to fill the shape of 
the targeted areas [14-16]. Upon the injection, it transforms into a soft gel at body temperature 
[14-16]. By protecting niosomes with an extra barrier and by preventing or decreasing the burst 
release, chitosan hydrogel can improve the release kinetics of drugs from niosomes and result in 
extended release rates. Also, as a localized delivery system, chitosan hydrogel can prevent the 
migration of niosomes away from the targeted tumor sites. Finally, chitosan has a mucoadhesive 
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property which can be used in the targeting of the tumor cells with the mucin over expression 
such as ovarian carcinoma and other adenocarcinomas [17, 18].  
To further improve the specific delivery of drugs to tumor cells we have incorporated 
Chlorotoxin (CTX). CTX is a 36-amino acid peptide derived from the venom of the scorpion 
Leirius quinquestriatus with known specificity toward tumor cells of neuroectodermal origin, 
such as glioma, but not to normal non-transformed cells.[19-21] Many studies have shown its 
application as an imaging and targeting agent for drug and radioisotope delivery.[22-25] A 
bioconjugat of CTX and Cy5.5 (a near-infrared fluorescent molecule) recently has been entered 
clinical trials.[26] By specific targeting of tumor cells with a fluorescent dye, this bioconjugat 
allows surgeons to distinguish normal tissue from malignancies such as glioma, prostate cancer, 
intestinal cancer, and sarcoma.[22, 26] As a targeting agent, CTX has been investigated in many 
drug delivery systems including CTX-conjugated iron oxide nanoparticles, CTX-modified 
doxorubicine-loaded liposomes, and CTX-assisted nanoparticle-chitosan hydrogel 
complexes.[27-29] 
In this study, we performed the release rate studies on niosomes and niosomes embedded 
in chitosan hydrogel with and without CTX to examine the effect of chitosan and CTX on the 
release rates. We used Transmission Electron Microscopy (TEM) for morphologic assessments, 
and Attenuated Total Reflectance-Fourier Transform Infra-Red (ATR-FTIR) spectroscopy to 
study the possible interactions between CTX and niosomes.  
2.3. Materials and Methods 
2.3.1. Materials 
Chlorotoxin was purchased from Iris Biotech GmbH (Marktredwitz, Germany). Span 60, 
cholesterol, dicetyl phosphate (DCP), medium molecular weight chitosan and 5(6)-
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Carboxyfluorescein dye were obtained from Sigma-Aldrich (St. Louis, MO). β-glycerophosphate 
disodium salt (β-GP) was purchased from Calbiochem EMD Biosciences (La Jolla, CA) and 
used as the crosslinking agent. All the other reagents were purchased from Fisher Scientific (Fair 
Lawn, NJ).  
2.3.2.  Preparation of Niosomes 
Dye-loaded niosomes were prepared by the thin film hydration method [4]. Briefly, span 
60, cholesterol and DCP (1:1:0.1 molar ratio) were dissolved in chloroform and transferred to a 
50 mL round bottom flask. To make a thin film, chloroform was removed by rotating the flask 
using a Buchi rotary evaporator (Flawil, Switzerland) in a water bath at 60oC. The thin film was 
left in the fume hood overnight to remove any remaining traces of the chloroform. The dried thin 
film was hydrated with dye solution with concentration of 5 mM in phosphate buffer saline 
(PBS) in the rotary evaporator for 1 h at 60oC. Size reduction process was performed using an 
Avanti Polar Lipids Mini-Extruder (Alabaster, AL) by passing the niosome suspension through 
800, 400 or 80 nm polycarbonate membrane filters (Nuclepore Corp., Pleasanton, CA) at 60oC. 
The un-trapped dye was separated from niosome suspension using a Beckman XL-100 
ultracentrifuge (Fullerton, CA) operating at 60,000 rpm for 1 h. Dye-loaded niosomes in the 
precipitate were resuspended in 0.01 M PBS and kept at 4oC for the future experiments.  
2.3.3. Preparation of Chitosan Hydrogel 
A 2.8% (w/v) chitosan solution was prepared by dissolving chitosan powder in 1.5 ml of 
0.1 M hydrochloric acid at room temperature. A -GP solution at a concentrations of 65% (w/v) 
was prepared in 0.5 ml of deionized water and kept at 4oC for 1 h prior to crosslinking along with 
the chitosan solution. While stirring continuously, the cold β-GP solution was added drop wise to 
the cold chitosan solution. After adding the last drop, the final solution was stirred for 10 min. 
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0.7 ml of niosome suspension was added into the chitosan and -GP mixture followed by 5 min 
stirring. The prepared mixture was transferred into a 5 ml beaker and placed in a water bath at 37 
oC and allowed to gel (Figure 2.1).  
2.3.4. Release Studies - Niosomes  
The release rate of the entrapped dye from niosomes was studied at specified time 
intervals using the Dialysis method. Briefly, 100 l of niosome solutions were pipetted into 
Slide-A-Lyzer mini-dialysis units with a 10,000-molecular-weight-cutoff (MWCO) membrane 
(Pierce Biotechnology) floating in a mini-dialysis flotation device (Pierce Biotechnology). They 
were dialyzed against 100 ml of 0.01M PBS (pH 7.4) or salt-free water (pH 6.0) at 37oC. While 
stirring the release medium using the magnetic stirrer at 200 rpm, 500 l aliquots of the release 
medium were taken at specified time intervals and refilled with the same amount of the fresh 
medium. The cumulative amount of the released dye in collected samples was quantified in 
triplicates using a Fluorescence Plate Reader (Biotek, Flx800) at an excitation wavelength of 485 
nm and emission wavelength of 528 nm. 
2.3.5. Release Studies - Chitosan Hydrogels Containing Niosomes  
The prepared chitosan hydrogels containing niosomes with and without CTX were placed 
into 100 ml of deionized water (pH 6.8) at 37oC while stirred at 200 rpm. At specified time 
points 500 l aliquots of the release medium were collected and stored at 4oC for further 
analysis. After taking each sample, the same amount of the release medium was added into the 
container. 
2.3.6. Transmission Electron Microscopy  
Transmission electron microscopy (TEM) was used to assess the morphology of 
niosomes alone and niosomes with CTX. The TEM samples were prepared by placing a droplet 
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of the suspension (after appropriate dilution) on a 150-mesh carbon coated formvar copper grid 
(Electron Microscopy Sciences, Hatfield, PA) and allowed to adhere for 1 min. Following the 
removal of the excess solution using a filter paper, the samples were placed in a vacuum 
chamber for 10 min at 40oC. The samples were then viewed under an electron microscope (FEI 
Morgagni TEM) with an operating voltage of 80 kV. 
2.3.7. ATR-FTIR Spectroscopy 
A 100 l niosome suspension with and without CTX was introduced onto a 45o ZnSe flat 
crystal (Thermo Scientific, WI) and allowed to air dry for 1 hr. To remove any excess water, the 
formed films were exposed to an ultrapure nitrogen flux before collecting the spectra. The ATR-
FTIR spectra were obtained using a Nicolet 6700 spectrometer (Thermo Scientific, WI). The 
spectra in the 4000-400 cm-1 region were collected using 300 scans at a spectral resolution of 4 
cm-1. The data analysis was performed using OMNIC software (Thermo Scientific, WI). To 
ensure appropriate comparison between different samples, all the spectra were baseline 
corrected. 
2.4. Results and Discussion  
2.4.1. Release Studies - Niosomes  
The in-vitro release rate studies for niosomes were performed in PBS (pH 7.4) 
representing physiological condition and salt-free water (pH 6.0) representing tumor pH 
conditions. The release profiles of 5,6-carboxyfluorescein from niosomes are shown in Figure 
2.2. The fast release rates in both conditions within the first 24 hours may be a result of dye 
desorption from the surface of niosomes. The slow release rates after 24 h for niosomes exposed 
to PBS can be related to diffusion of dye from the bilayer of niosomes. Unlike niosomes in PBS, 
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the continuous fast release profiles from niosomes exposed to salt-free water were observed even 
after 24 h.  
As niosomes are considered to be osmotically active, exposing them to salt-free water 
increases their osmotic pressure and results in their swelling [1]. This increases the permeability 
of dye from the bilayer leading to faster and less sustained release rates in salt-free water as 
compared to their release rates in PBS. 
2.4.2. Release Studies - Chitosan Hydrogels Containing Niosomes 
To provide niosomes with more stability and to decrease the osmotic pressure effect on 
the release rates, niosomes were embedded in a chitosan hydrogel. The release profiles of 
niosomes embedded with and without CTX in chitosan hydrogel along with the bare niosomes 
exposed to salt-free water are presented in Figure 2.3. It can be clearly seen that the 
incorporation of niosomes in chitosan hydrogel extended the release rates particularly after 24 h. 
The fast release rates within the first 24 h are mostly associated with niosomes placed on the 
surface of hydrogel, while the slower release rates after 24 h are related to niosomes embedded 
after the edge of chitosan network which provides them with more stability. In fact, only 61% 
cumulative release occurred for niosomes embedded in chitosan hydrogel after 21 days of the 
exposure to salt-free water. To investigate the effect of CTX on the release profiles, the same 
release rate studies were performed for CTX and niosomes embedded in chitosan hydrogel. The 
release profiles of 5,6-carboxyfluorescein from this system is also presented in Figure 2.3. It is 
clear that having CTX along with niosomes in chitosan hydrogel slightly extends the release 
rates when compared to the release rates from niosomes alone in chitosan hydrogel. The slower 
release rates are possibly due to the extra protection that CTX provides for niosomes and 
enhances their stability. 
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2.4.3. Transmission Electron Microscopy  
To understand the possible interactions between niosome and CTX, TEM imaging was 
performed for samples of niosomes alone (Figure 2.4a) and niosomes in the presence of CTX 
(Figure 2.4b). As can be seen in Figure 2.4b, CTX forms micelles and binds to the surface of 
niosomes. The attachment of CTX to niosomes may be the reason for the extended release rates 
observed from CTX and niosomes in chitosan hydrogel, as CTX protects niosomes with extra 
layer and increases their stability. 
2.4.4. ATR-FTIR Spectroscopy 
Comparative spectra of Niosome, CTX, and CTX+Niosome in the frequency region of 
1800-1200 cm-1 are shown in Figure 2.5. The most notable peaks in the Niosome spectrum were 
observed at 1736 cm-1 and 1466 cm-1 assigned to (C=O)  and (CH2), respectively. Other peaks 
in the spectrum of Niosome include 1376, 1355, and 1300 cm-1 all assigned to CH2 and CH 
bending vibrations. A peak at 1246 cm-1 in the spectrum of Niosome indicates the (PO4-3) of 
dicetyl phosphate.  
Two prominent bands in the CTX spectrum were observed at 1645 cm-1 and 1545 cm-1 
correspond to amide I (C=O stretch) and amide II (NH bending and CN stretch) -helical 
structures, respectively. The band at 1516 cm-1 was assigned to (C-C) and (C-H) of Tyrosine 
ring. Similarly, the 1446 cm-1 peak was associated with (CH2) of Tyrosine and Phenylalanine 
amino acid side chains present in CTX. The peaks at 1408 cm-1 and 1388 cm-1 correspond to 
(C-N) of Glutamine and Methionine and w(CH2) of Tyrosine, respectively.  
Two significant spectral shifts were observed in the CTX+Niosome spectrum.: 1) the 
characteristic amide II peak at 1538 cm-1 in CTX shifts to 1549 cm-1 in CTX+Niosome, 2) the 
amide I peak at 1648 cm-1 in CTX shifts to 1657 cm-1 in CTX+Niosome.  
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It is known that the frequency changes in amide bands correlate with the strength 
alterations of the hydrogen bonds.[30-32] While an upshift represents weakening of hydrogen 
bonds in stretching vibrations, it indicates stronger hydrogen bonds for bending vibrations.[31] It 
has been shown that the shifts of amide II band induced by hydrogen bonding derive 
predominantly from N-H bending.[33] Therefore, the observed upshift of amide II band in the 
spectra of CTX+Niosome compared to CTX indicates an increase in N-H hydrogen bonding. 
This implies that a hydrogen bonding between N-H groups of CTX and C=O and O-H groups of 
Niosomes may be responsible for the observed binding of CTX to the surface of niosomes shown 
by TEM imaging. The upshift of amide I (C=O stretch) indicates a decrease in C=O associated 
intramolecular C=O…N-H hydrogen bonding within CTX. This may be due to the formation of 
intermolecular hydrogen bonds between N-H groups of CTX and O-H and C=O groups of 
Niosomes. 
2.5. Conclusions 
Embedding niosomes in chitosan hydrogel resulted in significant prolonged release 
profiles specifically after 24 h. Release rate studies also indicated that embedding CTX along 
with niosomes in chitosan hydrogel results in slightly more extended release rates as compared to 
the release rates from niosomes alone in chitosan hydrogel. As clearly shown by the TEM 
images, the attachment of CTX to the surface of niosomes may play a critical role in improving 
the stability of niosomes and the extended release rates. The interaction of CTX with niosomes 
was also confirmed by ATR-FTIR studies. These findings suggest that the developed drug 
delivery system with extended release profiles and distinct tumor targeting features would 
improve the specific delivery of anticancer drugs to tumor cells. 
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Figure 2.1 Schematic representation of the thermosensitive chitosan hydrogel preparation 
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Figure 2.2 Cumulative release profiles of 5,6-carboxyfluorescein from niosomes in salt-free 
water (pH 6.0) and PBS (pH 7.4) 
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Figure 2.3 Cumulative release profiles of 5,6-carboxyfluorescein from niosomes, niosomes 
embedded in chitosan hydrogel, and CTX-niosomes embedded in chitosan hydrogel in salt-free 
water (pH 6.0) 
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Figure 2.4 TEM images of bare niosomes (a) and niosomes  
with CTX (b) 
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Figure 2.5 ATR-FTIR absorption spectra of niosomes (dashed black), CTX (dashed gray), and 
niosomes with CTX (solid gray) in frequency region of 1800 cm -1–1200 cm -1 
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CHAPTER 3: CHARACTERIZATION OF PACLITAXEL-LOADED NIOSOMES 
EMBEDDED IN CHITOSAN HYDROGELS: THE INFLUENCE OF CROSSLINKER 
CONTENT AND PH  
 
3.1. Abstract 
We report the development and characterization of a localized drug delivery system 
consisting of paclitaxel-loaded non-ionic surfactant vesicles (PTX-loaded niosomes) embedded 
in a thermosensitive chitosan hydrogel. This system represents a new approach in cancer therapy 
through a sustained and controlled delivery of PTX to tumor sites.  
The characterization of prepared PTX-loaded niosomes was performed in terms of 
morphological assessments and encapsulation efficiency measurements. Chitosan hydrogels (L-
Ch, M-Ch, and H-Ch) were prepared with various crosslinker contents in their formulations. The 
PTX release from chitosan hydrogels containing PTX-loaded niosomes was evaluated in a 
release medium at 37 oC with pH 7.4 or 6.3 representing the extracellular pH of a normal tissue 
or tumor environment. The release studies showed a prolonged release of PTX form chitosan 
hydrogels containing PTX-loaded niosomes with similar release profiles for L-Ch and M-Ch 
hydrogels. 
The mathematical modeling of the PTX release data was performed using the Peppas-
Korsmeyer model to understand the mechanisms of PTX release from chitosan hydrogels 
containing PTX-loaded niosomes. A combination of diffusion-controlled and swelling-controlled 
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release also known as the anomalous transport was identified as the dominant release mechanism 
only for L-Ch hydrogels at pH 6.3.  
Swelling studies of the chitosan hydrogels were also performed in the same conditions 
used for the drug release studies. Swelling of chitosan hydrogels was observed for the 
formulations with low and medium crosslinker contents (L-Ch and M-Ch) when incubated at pH 
6.3. No significant difference in the swelling ratio of chitosan hydrogels with a high crosslinker 
content (H-Ch) was found at pH 6.3 or 7.4.  
Together the results suggest that the chitosan hydrogels containing PTX niosomes could 
improve the chemotherapeutic benefits of PTX by providing a localized, controlled, and 
prolonged delivery in solid tumors.  
3.2. Introduction 
Paclitaxel (PTX) is one of the most effective chemotherapeutic agents in the treatment of 
many cancers including breast, ovarian, colon, and non-small-cell lung cancers [1-4]. Due to the 
hydrophobicity of PTX, several organic formulations such as polyethoxylated castor oil 
(Cremophor® EL) have been employed to improve the solubility of PTX [5]. However, many 
undesired side effects of Cremophor EL have been reported in patients undertaking this 
treatment [6-8].  
Among different strategies, encapsulation of PTX in submicronic colloidal systems such 
as liposomes, microspheres, micelles, and polymeric nanoparticles has been widely studied to 
address this problem [9-11]. Despite having many promising features, poor stability and low 
bioavailability of the nanoparticles in tumor sites have hindered their effectiveness when 
administered systemically [12-14].  
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An alternative approach is the use of localized drug delivery systems in which 
chemotherapeutic agents are encapsulated in a matrix designed in various forms including 
hydrogels, films, wafers, and rods [15]. Among different in situ drug delivery systems, 
thermoresponsive chitosan hydrogels in particular have gained special attention [16-18]. Their 
initial liquid state at room temperature allows them to be applied through a simple injection into 
the specific body sites. After injection, they transform into a soft gel at body temperature which 
provides a localized drug release within the tumor sites [19]. In addition, they are known to 
exhibit antibacterial, biocompatible, biodegradable, and mucoadhesive properties [20-22]. 
Thermoresponsive chitosan hydrogel systems have been prepared with different chemical or 
physical crosslinking methods [16, 23]. 
Despite all the outstanding properties, some limitations are associated with their use [24] 
First, due to the presence of high amount of water in the hydrogel network, the encapsulation of 
hydrophobic drugs such as PTX is often difficult [24]. Second, the large pores in their network 
structure can cause relatively fast release rates particularly for small molecule drugs [25]. To 
address these challenges, an incorporation of a secondary drug carrier such as liposomes, 
micelles, and other particle based vehicles into the hydrogel network has been considered [26-
28]. 
In this study, we present the development of a localized drug delivery system consisting 
of PTX-loaded non-ionic surfactant vesicles (niosomes) embedded in a thermoresponsive 
chitosan hydrogel network. Similar to liposomes, niosomes have a spherical bilayer structure 
with hydrophilic core and hydrophobic shell allowing them to be used for encapsulating both 
hydrophilic and hydrophobic drugs [29-31].  
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The PTX-loaded niosomes were prepared using the thin film hydration method and 
characterized by performing morphological assessments and encapsulation efficiency 
measurements. Chitosan hydrogels containing PTX-loaded niosomes with various crosslinker 
contents were prepared. The PTX release studies were performed in a release medium with pH 
7.4 or 6.3. The PTX release kinetics were evaluated by fitting the release data into the Peppas-
Korsmeyer model. Swelling and biodegradability are among the important characteristics of 
chitosan hydrogels [21, 38]. Therefore, swelling behavior and degradation rates of chitosan 
hydrogels were also studied.   
3.3. Materials and Methods 
3.3.1. Materials 
Span 60, cholesterol, dicetyl phosphate (DCP), and medium molecular weight chitosan 
were purchased from Sigma-Aldrich (St. Louis, MO). The crosslinking agent, β-
glycerophosphate disodium salt (β-GP) was purchased from Calbiochem EMD Biosciences (La 
Jolla, CA). Paclitaxel (PTX) was obtained from LC laboratories (Woburn, MA) and used as a 
chemotherapeutic drug. All the other agents were purchased from Fisher Scientific (Fair Lawn, 
NJ).  
3.3.2. Preparation of PTX-loaded Niosomes 
PTX-loaded niosomes were prepared by the thin film hydration method [31]. Briefly, 
span 60, cholesterol and DCP (1:1:0.1 molar ratio) were dissolved in chloroform and transferred 
to a 50 mL round bottom flask. PTX at 0.5 to 10 mol% with respect to total niosome content was 
added to this solution. To make a thin film, chloroform was removed by rotating the flask using a 
Buchi rotary evaporator (Flawil, Switzerland) in a water bath at 60oC. The thin film was left in 
the fume hood overnight to remove any remaining traces of the chloroform. The dried thin film 
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was hydrated with 0.01 M phosphate buffer saline (PBS) containing 0.1% (v/v) Tween 80 in the 
rotary evaporator for 1 h at 60oC. Size reduction process was performed using an Avanti Polar 
Lipids Mini-Extruder (Alabaster, AL) by passing the niosome suspension through 800, 400 or 80 
nm polycarbonate membrane filters (Nuclepore Corp., Pleasanton, CA) at 60oC. The un-trapped 
drug was separated from niosome suspension using a Beckman XL-100 ultracentrifuge 
(Fullerton, CA) operating at 60,000 rpm for 1 h. PTX-loaded niosomes in the precipitate were 
resuspended in 0.01 M PBS and kept at 4oC for the future experiments.  
3.3.3. Characterization of PTX-loaded Niosomes 
3.3.3.1. Transmission Electronic Microscopy  
The morphology of PTX-loaded niosomes was observed using transmission electron 
microscopy (TEM). The TEM samples were prepared by placing a droplet of niosome 
suspension (after appropriate dilution) on a 150-mesh carbon coated formvar copper grid 
(Electron Microscopy Sciences, Hatfield, PA) and allowed to adhere for 1 min. Following the 
removal of the excess solution using a filter paper, the samples were placed in a vacuum 
chamber for 10 min at 40oC. The samples were then viewed under an electron microscope (FEI 
Morgagni TEM) with an operating voltage of 80 kV. 
3.3.3.2. Encapsulation Efficiency 
The encapsulation efficiency of PTX in niosomes was determined using a Shimadzu 
HPLC system consisting of an automatic sample injector (SIL-10A), system controller (SCL-
10A VP), pump (LC-10AT VP), degasser (DGU- 14A), and UV-VIS detector (SPD-10A VP). 
Chromatographic separation of PTX was achieved using a reverse phase C18 column (ODS-3V, 
GL Sciences). The mobile phase consisted of acetonitrile and water (60:40 v/v). The flow rate 
was 1.0 ml/min and the injection volume was 20 l. The UV detection was performed at a 
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wavelength of 227 nm. Prior to HPLC analysis, PTX was extracted from the niosomes using 
dichloromethane (DCM). Briefly, 2 ml of prepared niosome solution was extracted with 3×1 ml 
of DCM. Following the evaporation of DCM under a stream of nitrogen, the extracted PTX was 
dissolved in 4 ml of acetonitrile and quantitated using the HPLC system. The extraction 
efficiency was determined by extracting a known amount of PTX following the same procedure 
as described above. The encapsulation efficiency was defined as the ratio of PTX encapsulated in 
niosomes to the initial amount of PTX used in niosomes preparation: 
	Encapsulation	Efficiency		ሺ%ሻ ൌ ୅୫୭୳୬୲	୭୤	୔୘ଡ଼	ୣ୬ୡୟ୮ୱ୳୪ୟ୲ୣୢ	୧୬	୬୧୭ୱ୭୫ୣୱ୍୬୧୲୧ୟ୪	ୟ୫୭୳୬୲	୭୤	୔୘ଡ଼	୳ୱୣୢ	୧୬	୬୧୭ୱ୭୫ୣ	୮୰ୣ୮ୟ୰ୟ୲୧୭୬ 		ൈ 100 ….……….…(1) 
3.3.4. Preparation of Chitosan Hydrogels 
A 2.8% (w/v) chitosan solution was prepared by dissolving chitosan powder in 1.5 ml of 
0.1 M hydrochloric acid at room temperature. A -GP solution at three different concentrations 
of 55%, 65%, or 83% (w/v) was prepared in 0.5 ml of deionized water and kept at 4oC for 1 h 
prior to crosslinking along with the chitosan solution. While stirring continuously, the cold β-GP 
solution was added drop wise to the cold chitosan solution. After adding the last drop, the final 
solution was stirred for 10 min. 0.7 ml of niosome suspension was added into the chitosan and -
GP mixture followed by 5 min stirring. The prepared mixture was transferred into a 5 ml beaker 
and placed in a water bath at 37 oC and allowed to gel. Chitosan hydrogels were named as L-Ch, 
M-Ch, or H-Ch representing low (0.33 M), medium (0.39 M) or high (0.50 M) concentrations of 
-GP in hydrogel formulations. 
3.3.5. In vitro Release Studies  
Prepared samples of chitosan hydrogel containing PTX-loaded niosomes were placed into 
30 ml of PBS (pH=7.4 or 6.3) at 37oC. 0.1% (v/v) Tween 80 was also included in the release 
medium as a sink-inducing agent to facilitate the solubility of PTX [4, 5]. At predetermined time 
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intervals, the entire release medium was collected and replaced with equal amount of fresh 
medium at 37oC. The collected samples were pretreated using the DCM extraction procedure and 
then introduced to the HPLC system as described in section 3.3.2.  
3.3.6. Mathematical Analysis of the Drug Release Kinetics 
To determine the release kinetics of PTX from niosome embedded chitosan hydrogel 
complexes and the related transport mechanisms, the obtained drug release rate data were fitted 
into the Peppas-Korsmeyer semi-empirical equation also known as power law equation [32]: 
ܳ ൌ ቀெ೟ெቁ ൌ 	݇ ൈ ݐ௡ ……………………………………………………………………………(2) 
where Q is the fractional drug release into the medium at time t (h), Mt is the amount of drug 
released at time t, M is the total amount of drug, k is the kinetic constant incorporating structural 
and geometric characteristics of the drug delivery system, t is the release time (h) and n is the 
diffusion exponent characterizing the drug release mechanism.  
Based on the diffusion exponent, the drug release mechanisms from a hydrogel system 
can be classified as [32, 33]:  
1- Quasi-Fickian diffusion,     n < 0 .5  
2- Fickian diffusion,     n = 0 .5  
3- Anomalous transport,    0.5 < n < 1 
4- Case II transport (swelling-controlled drug release),      n =1 
3.3.7. Swelling Studies 
The swelling behavior of chitosan hydrogels was studied as follows.Uniform disk-shaped 
chitosan hydrogels were immersed into 30 ml PBS with pH = 7.4 or 6.3 at 37oC. At specific time 
points the hydrogels were taken out from the swelling medium and blotted using a filter paper to 
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remove the excess surface water. This was followed by measuring their diameter. The swelling 
ratio was defined as: 
%	Swelling	ratio ൌ 	 ୈ౏ୈౚ  ……………………………………………………..………………….(3) 
Ds and Dd correspond to the diameter of the hydrogel at the swollen and dried states, 
respectively. 
3.3.8. Enzymatic Degradation 
Samples of chitosan hydrogel were prepared using the same method described in the 
previous section and placed into 30 ml of PBS (pH=7.4) with 0.02 mg/ml lysozyme at 37oC. At 
specified time points samples were removed from the medium, rinsed with distilled water, and 
dried under vacuum. Enzymatic degradation of chitosan hydrogel samples is then quantified 
using the following equation: 
%	ܧ݊ݖݕ݉ܽݐ݅ܿ	ܦ݁݃ݎܽ݀ܽݐ݅݋݊	ሺݐሻ ൌ 	 ሾௐబିௐ೟ሿௐబ  …………………………………………………(4) 
W0 reflects the initial weight of the chitosan hydrogel and Wt is the weight of the dried hydrogel 
at time t. 
3.4. Results and Discussion 
3.4.1. Characterization of PTX-loaded Niosomes 
The mean diameter and encapsulation efficiency of PTX in PTX-loaded niosomes as a 
function of the membrane pore size used in the extrusion process are shown in Figure 3.1a. 
Niosomes with a mean diameter of 85 nm were prepared using a membrane with a pore size of 
80 nm. A decrease in encapsulation efficiencies was observed for niosomes when smaller 
membrane pore sizes used in the extrusion process which correlated well with the decrease of 
niosome sizes. 
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TEM image of a PTX-loaded niosome which was extruded through 80 nm membrane 
with a diameter of less than 100 nm is shown in Figure 3.1b. 
3.4.2. In vitro Release Studies 
The cumulative release profiles of L-Ch, M-Ch and H-Ch hydrogels containing PTX-
loaded niosomes in PBS with pH=7.4 and 6.3 are depicted in Figure 3.2a-c. Slow and controlled 
PTX release profiles were observed for all hydrogels with various cross-linker content in both 
release media (pH=6.3 and 7.4). All the hydrogels indicated slower release profiles in the release 
medium with pH=6.3 as compared to the release medium with pH=7.4. The PTX cumulative 
release profiles from L-Ch and M-Ch hydrogels were very similar particularly in PBS with 
pH=6.3 for which only 38% and 37% of the cumulative release occurred after 40 days, 
respectively. Higher amounts of PTX release were observed for L-Ch (44%) and M-Ch (43%) 
incubated in PBS with pH=7.4 for 40 days as compared to the hydrogels incubated in PBS with 
pH=6.3.  
H-Ch hydrogels indicated significantly slower release profiles of PTX compared to both 
L-Ch and M-Ch hydrogels. Only 33% and 36% of the PTX release occurred from H-Ch 
hydrogels after 40 days in the release media with pH=6.3 and 7.4, respectively. As can be seen in 
Figure 3.2a-c, unlike L-Ch and M-Ch the difference between the release profiles of H-Ch in PBS 
with pH 6.3 and 7.4 were not as significant as those observed for L-Ch and M-Ch hydrogels.  
The PTX release rates for all chitosan formulations were slower in PBS with pH 6.3 than 
PBS with pH 7.4.This phenomenon can be explained as follows. As niosomes contain dicetyl 
phosphate, a negative charge inducer, they possess negative zeta potential values [31, 34, 35]. 
Therefore, they are likely to interact with positively charged NH2 groups in chitosan hydrogel 
when incubated in PBS with low pH (6.3). The slower release rates observed for the chitosan 
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hydrogels containing PTX-niosomes in PBS with pH 6.3 compared to PBS with pH 7.4 might be 
due to the possible interactions between negatively charged niosomes and NH3+ groups of 
chitosan hydrogels when incubated in PBS with pH 6.3. 
3.4.3. Mathematical Analysis of the Drug Release Kinetics 
The drug release kinetics of PTX from L-Ch, M-Ch, and H-Ch hydrogels containing 
PTX-loaded niosomes were further assessed by fitting the PTX release data to the Peppas-
Korsmeyer model. The corresponding theoretical curves are presented as dashed lines in Figure 
3.2a-c. The model coefficients (k and n) and the squared correlation coefficient (R2) are listed in 
Table 3.1. A good correlation with the Peppas-Korsmeyer model (R2 > 0.91) was obtained for all 
the PTX release data. 
Based on the derived release exponent values (0.5 < n < 1), the PTX release can be 
classified as an anomalous transport for L-Ch hydrogels when incubated in PBS with pH 6.3 
indicating that the drug release from this system was a combination of diffusion-controlled 
(n=0.5) and swelling-controlled (n =1) release. The drug release from M-Ch and H-Ch hydrogels 
containing PTX-loaded niosomes in PBS with pH 6.3 was identified as Fickian diffusion 
(n=0.5). When incubated in PBS with pH 7.4, n< 0.5 was obtained for all hydrogels (L-Ch, M-
Ch, and H-Ch) identifying the PTX release mechanism as quasi-Fickian diffusion.  
3.4.4. Swelling Studies 
The swelling studies were performed on the L-Ch, M-Ch, and H-Ch hydrogels containing 
PTX-loaded niosomes which were incubated in PBS with pH=7.4 and 6.3 for specified time 
points to analyze the effect of crosslinker content on the swelling behavior of chitosan hydrogels 
at various pH. The swelling ratio was defined as the diameter of the swollen hydrogel to the 
diameter of the hydrogel at the dried state.  
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Figure 3.3 shows a comparative representation of L-Ch, M-Ch, and H-Ch hydrogels after 
24 h of incubation in PBS with pH=7.4 and 6.3. As can be seen in Figure 3.3, the swelling 
behavior of chitosan hydrogels varies as a function of the crosslinker content and pH of the 
release medium. 
While L-Ch and M-Ch hydrogels exhibited increased swelling ratios at pH=6.3 when 
compared to pH=7.4, no significant difference was observed for H-Ch hydrogels at various pH 
conditions.  
Swelling ratios of these hydrogels at pH=7.4 and 6.3 as a function of time are shown in 
Figure 3.4. The highest swelling ratio was observed for L-Ch hydrogel after 24 h of incubation in 
PBS with pH=6.3. The swelling ratios decreased after 24 h and all the hydrogels reached 
equilibrium swelling after 7 days. Similar to the swelling ratios at 24 h, L-Ch hydrogels at 
pH=6.3 had the highest swelling ratios among other hydrogels for all incubation time periods. 
These results are in agreement with the previous studies in which the swelling of chitosan 
hydrogels has been reported to be a function of crosslinker content and the pH of the release 
medium [37].  
At low pH (pH < 6.5), a protonation of amino groups in chitosan hydrogels occur. 
Therefore, the observed swelling of L-Ch and M-Ch hydrogels at pH 6.3 can be explained as an 
increase in the protonation and repulsion of chitosan free ammonium groups. 
3.4.5. Enzymatic Degradation 
Biodegradability is one of the important characteristics of chitosan hydrogels [21, 38]. To 
determine the degradation rate of chitosan hydrogels, M-Ch hydrogels were incubated in PBS 
with and without 0.02 mg/ml lysozyme concentration at 37 oC. As can be seen in Figure 3.5, 
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around 75% degradation occurred for M-Ch hydrogel after49 days of incubation in PBS with 
0.02 mg/ml lysozyme. 
Degree of deacetylation (DDA) has been defined an important factor in degradation of 
chitosan hydrogels [39, 40]. In this study chitosan with DDA of 85% was used. Chitosan with 
high DDA (71% to 93%) has been shown to experience slow degradation rates.  
3.5. Conclusions 
We have prepared thermosensitive chitosan hydrogels containing PTX-loaded niosomes 
with various amount of crosslinker in their formulations. We have shown that the incorporation 
of PTX-niosomes in chitosan hydrogels resulted in prolonged release profiles which lasted for 
more than 40 days in a pH-dependent manner. While L-Ch and M-Ch hydrogels indicated 
similar PTX release profiles, relatively slower release rates (around 10%) were found for H-Ch 
hydrogels. The release mechanism was identified as anomalous transport (a combination of 
diffusion-controlled and swelling-controlled release) for L-Ch hydrogels when incubated in PBS 
with pH 6.3. The significant effect of crosslinker content on physical properties and release 
profiles of chitosan hydrogels was further confirmed by swelling studies. Major changes in 
swelling behavior were observed for L-Ch and M-Ch chitosan hydrogels with a small 
physiologically relevant pH change. Together, the results of this study show promise for the 
development of a localized drug delivery system which can be used for a sustained and 
controlled delivery of PTX at the tumor sites.  
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Figure 3.1 Mean diameter and encapsulation efficiency of niosomes as a function of membrane 
pore size used in the extrusion process (a), TEM image of a PTX-loaded niosome with a 
diameter of less than 100 nm (b) 
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Figure 3.2 Cumulative release profiles of PTX from L-Ch Nio (a), M-Ch Nio (b), and H-Ch Nio 
(c) in PBS with pH=7.4 or 6.3. The dashed lines represent the corresponding theoretical curves 
derived from Korsmeyer-Peppas model. 
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Table 3.1 Kinetic assessment of drug release from chitosan hydrogels containing PTX-loaded 
niosomes using Korsmeyer-Peppas model 
Sample Korsmeyer-Peppas model Drug release mechanism
    k n R
2
      
L-Ch Nio - PBS  pH =6.3 1.18 0.57 0.98 Anomalous transport  
L-Ch Nio - PBS  pH =7.4 1.88 0.46 0.91 Quasi-Fickian diffusion 
M-Ch Nio - PBS  pH =6.3 1.21 0.50 0.98 Fickian diffusion 
M-Ch Nio - PBS  pH =7.4 1.59 0.48 0.97 Quasi-Fickian diffusion 
H-Ch Nio - PBS  pH =6.3 1.01 0.50 0.92 Fickian diffusion 
H-Ch Nio - PBS  pH =7.4 1.20 0.49 0.92 Quasi-Fickian diffusion 
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Figure 3.3 Comparative representation of swelling behavior of L-Ch, M-Ch, and H-Ch hydrogels 
after 24 h of incubation in PBS with pH=7.4 or 6.3. The scale bars correspond to 1 cm. 
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Figure 3.4 Swelling ratios of L-Ch, M-Ch, and H-Ch hydrogels at pH=7.4 and 6.3.  
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Figure 3.5 Degradation of M-Ch, hydrogels as a function of time incubated in PBS with 0.02 
mg/ml lysozyme (filled purple) and PBS (open purple) at pH=7.4  (a) and images of M-Ch 
hydrogels prior and 21 days after incubation in PBS with 0.02 mg/ml lysozyme (b) 
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CHAPTER 41: A CELL ELISA FOR THE QUANTIFICATION OF MUC1 MUCIN 
EXPRESSED BY CANCER CELLS OF EPITHELIAL AND NEUROECTODERMAL 
ORIGIN 
 
4.1. Abstract 
Quantitative analysis of MUC1, a cell membrane associated mucin, expressed by intact 
cells of epithelial origin previously has been limited to flow cytometry, which requires using 
large quantities of cells and antibodies. Here, for the first time, we report the development of a 
novel Cellular-based Enzyme Linked Immunosorbent Assay (Cell ELISA) to quantify the 
expression of MUC1 by cell lines of epithelial and neuroectodermal origin using an antibody 
recognizing a specific tandem repeat found in the extracellular domain of MUC1. In contrast to 
flow cytometry, this method requires a much lower number of cells. We report here the results 
obtained from two variants of this Cell ELISA in live and fixed cells. We found that the Cell 
ELISA in live cells was not sensitive enough to detect a difference in MUC1 levels between the 
normal cells and tumor cells. However, we found that Cell ELISA in fixed cells followed by 
whole cell staining was a dependable method of MUC1 level detection in the normal and tumor 
cells showing significantly higher levels of MUC1 receptor in the tumor cells when compared to 
the normal controls. Therefore, we conclude that the Cell ELISA in fixed cells is an efficient 
                                                 
1 Note. “A CELL ELISA FOR THE QUANTIFICATION OF MUC1 MUCIN (CD227) EXPRESSED BY 
CANCER CELLS OF EPITHELIAL AND NEUROECTODERMAL ORIGIN” Falahat, Rana, et al., 2015, Cellular 
Immunology, Vol. 298, No. 1, Copyright © 2016 by Elsevier Inc. Permission is included in Appendix A.  
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method for quantifying the expression of MUC1 by epithelial and neuroectodermal cancer cell 
lines.  
4.2. Introduction 
MUC1 mucin (CD227), a large glycoprotein, is expressed on the surface of normal 
glandular epithelial cells and has been found to be aberrantly overexpressed on most carcinoma 
cells [1, 2]. In addition to being an important and valuable diagnostic tumor marker, MUC1 has 
been studied as a potential therapeutic target [3, 4]. Recent advances in MUC1 associated cancer 
therapies, including immunotherapy [5, 6] and targeted drug delivery [7-9], have created a need 
for quantitative assessment of MUC1 in various tumor cells. Until now, the expression of MUC1 
on the surface of intact cells has been quantified using flow cytometry [10-12], which, despite its 
sensitivity to detect cell surface antigens, requires a large number of cells [13, 14]. Cell ELISA, 
as described here, is based on the interaction between antibodies and cell surface antigens 
assisted by colorimetric (or near infrared) methods of antigen detection. It has been shown to be 
as sensitive as flow cytometry, and it is a commonly used method for quantification of surface 
antigens [15-17]. The aim of this study was to develop a Cell ELISA technique to quantify the 
expression level of MUC1 in various tumor cells and compare it to the normal controls. Our 
study included the design of two variants of Cell ELISA using live cells and fixed cells. Flow 
cytometry and Western blot were used to validate the developed Cell ELISA assays. 
4.3. Materials and Methods 
4.3.1. Cell Lines 
The following cell lines were used: human ovarian epithelial origin carcinoma OV2008, 
SV-40 large T-antigen transfected normal human ovarian surface epithelial cells IMCC3 (both 
provided by Dr. Patricia Kruk, Department of Pathology and Cell Biology, College of Medicine, 
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University of South Florida, Tampa, FL), two human glioblastoma astrocytoma cell lines U87 
and U373 (both from American Type Culture Collection) and mouse glioma G26 [18, 19]. The 
ovarian cell lines (OV2008 and IMCC3) were cultured in a 1:1 mixture of MCDB105/M199 
medium (Sigma-Aldrich, MO) supplemented with 5% fetal bovine serum (FBS; Hyclone, UT) 
and 10 g/ml Gentamicin. The G26, U87, and U373 cell lines were grown in Minimum Essential 
Medium with Earle’s Balanced Salts (MEM/EBSS; Hyclone, UT) supplemented with 10% FBS 
and 2 mM L-glutamine, penicillin, and streptomycin. All cell lines were grown in 25 cm2 culture 
flasks (Corning, NY) and incubated at 37oC with 5% CO2. 
4.3.2.  Antibodies  
VU-11D1, a mouse primary (Ab1) monoclonal antibody recognizing TSAPDTR, the 7-
mer epitope found in the extracellular domain of MUC1 protein, HRP-conjugated polyclonal 
goat anti-mouse secondary IgG antibody (Ab2) (both from NOVUS Biologicals, CO), goat anti-
mouse IgG-PE (Santa Cruz Biotechnology, CA), and anti-α-Tubulin monoclonal antibody 
(T6199) (Sigma-Aldrich, MO) were used in this study.  
4.3.3. Cell ELISA using Live Cells  
The first assay, Cell ELISA using live cells, was performed as follows. After detaching 
cells from the culture flask and adjusting the cell density to 3×105 cells/ml, 100 l of the cell 
suspension (3×104 cells/well) was added to each well of a flat-bottomed 96-well microtiter plate 
(Corning, NY). The plate was incubated overnight with an appropriate growth medium at 37oC 
in 5% CO2. The following day, the medium was removed, and the confluent cell monolayers 
were washed 3 times with 200 l/well of washing buffer (0.01 M Phosphate Buffered Saline 
(PBS) containing 0.5% (w/v) Bovine Serum Albumin (BSA) (Sigma-Aldrich, MO)). Nonspecific 
binding was blocked using 100 l/well of blocking solution containing 2% (v/v) normal goat 
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serum (Southern Biotech, AL) and 1% (w/v) BSA in 0.01 M PBS for 1 hour at 4oC. The cells 
were treated under one of the following experimental conditions: 1) primary antibody alone 
(Control Ab1); 2) secondary antibody alone (Control Ab2); 3) primary and secondary antibody 
together (Ab1 + Ab2); or 4) blocking solution alone (Cell Control). Both primary and secondary 
antibodies were prepared in the blocking solution. Upon the removal of the blocking solution 
cells received either 50 l/well of the primary antibody or 50 l/well of the blocking solution 
followed by incubation for at least 1 hour at 4oC. The plate was washed 5 times with 200 l/well 
of the washing buffer and then exposed to 50 l/well of the secondary antibody or 50 l/well of 
the blocking solution and incubated for additional 1 hour at 4 oC. The plate was washed 5 times 
with 200 l/well of the washing buffer. Then, 100l of TMB (3,3', 5,5"-tetramethylbenzidine) 
substrate solution (Cell Signaling Technology, MA) was added to each well, and the reaction 
was allowed to proceed for 20 minuets at room temperature. The enzyme reaction was stopped 
by the addition of 25 l/well of 2 M sulfuric acid. The optical density (OD) at 450 nm was 
measured using an ELx800 microplate reader (Bio-Tek Instruments, VT).  
4.3.4.  Cell ELISA using Fixed Cells  
In this variant of Cell ELISA, a fixation step was used to prevent loss of cells during the 
procedure. This assay is analogous to Cell ELISA in live cells and the same experimental 
treatment groups (Control Ab1, Control Ab2, Ab1+Ab2, and Cell Control) were used as 
described in section 4.3.3. Briefly, cells were seeded in a flat-bottomed 96-well microtiter plate 
at 3×104 cells/well in the appropriate growth medium. Following the incubation for 24 hours at 
37oC in 5% CO2, the growth medium was removed and the confluent cell monolayers were 
washed 3 times with 0.01 M PBS (200 l/well) and fixed with 4% (v/v) paraformaldehyde 
(Electron Microscopy Sciences, PA) in 0.01 M PBS (100 l/well) for 10 minutes at room 
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temperature. The fixed monolayers were washed 3 times with 0.01 M PBS (200 l/well) and 
then permeabilized with 50 l/well of the blocking solution (0.01 M PBS containing 2% (v/v) 
normal goat serum, 1% (w/v) BSA, and 0.1% (v/v) Triton X-100) for 1 hour at room 
temperature. Upon the removal of the blocking solution cells received 50 l/well of the primary 
antibody or 50 l/well of the blocking solution and were incubated for at least 1 hour at room 
temperature. The plate was washed 3 times with 0.01 M PBS (5 minutes each) and then exposed 
to 50 l/well of the secondary antibody or 50 l/well of the blocking solution and incubated for 1 
hour at room temperature. After washing with 0.01 M PBS (3 times, 5 minutes each), the plate 
was incubated with the TMB substrate solution (100 l/well) at room temperature. The reaction 
was allowed to proceed for 20 minuets. The enzyme reaction was stopped by adding 25 l/well 
of the stop solution, followed by reading the OD at 450 nm using a microplate reader.  
4.3.5. Quantification of the Cell Number in Cell ELISA using Fixed Cells 
After removing the plate contents, 50 μL/well of 1X Janus Green stain (Abcam, MA) was 
added to the plate and incubated for 5 minutes at room temperature. Next, the plate was washed 
5 times with 200 l/well of deionized water followed by the addition of 50 μL/well of 0.5 M 
HCl. The OD at 595nm was measured using the ELx800 microplate reader. The results were 
analyzed by normalizing OD values measured at 450 nm to cell number ([OD450] / [OD595]) to 
account for differences in cell numbers in various wells. All washing and incubation  steps 
(except for the overnight incubation) were performed on a plate shaker (Bellco Biotechnology, 
NJ) with gentle shaking at 300 rpm.  
4.3.6. Flow Cytometry 
Flow cytometry analysis was performed on OV2008 cells as follows: cells were 
trypsinized from adherent cultures and resuspended in the blocking solution (0.01 M PBS 
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containing 2% (v/v) normal goat serum and 1% (w/v) BSA). After adjusting the cell density to 
5×106 cells/ml, 100 l of the cell suspension (5×105 cells) was added to micro-centrifuge tubes 
and incubated for 1 hour at 4oC. The same experimental treatment groups (Control Ab1, Control 
Ab2, Ab1+Ab2, and Cell Control) were used for flow cytometry as described in section 4.3.3.  
Upon the removal of the blocking solution cells received either 100 l of the primary 
antibody or 100 l of the blocking solution followed by incubation for at least 1 hour at 4oC. The 
samples were washed 3 times with the washing buffer (0.01 M PBS containing 1% (w/v) BSA) 
by centrifugation at 400 g for 5 minutes and then exposed to 100 l of the goat anti-mouse IgG-
PE secondary antibody or 100 l of the blocking solution and incubated for 30 minutes at 4oC in 
the dark. After washing (3 times, 5 minutes each), the samples were re-suspended in 0.01 M PBS 
and stained with 7-Aminoactinomycin D (7-AAD) viability dye (BD Pharmingen, CA) for 15 
minutes to distinguish live cells (7-AAD negative) from dead cells (7-AAD positive).  
Flow cytometry was performed on aliquots of each sample using an Accuri C6 flow 
cytometer (BD Biosciences, CA) and obtained data was analyzed using CFlow Plus software 
(BD Biosciences, CA). A minimum of 50,000 events was collected on each sample. Staining 
intensity was determined in 2-dimensional histograms of fluorescence intensity versus cell 
number. After gating the 7-AAD-negative cell population, the percentage of live cells expressing 
PE was determined.  
4.3.7. Western Blot 
Cells were grown to 70% confluence and washed with ice-cold 0.01 M PBS and detached 
using scrapping. Cells were pelleted and suspended in 2× RIPA buffer (50 mM Tris-buffered 
saline [TBS], pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium 
dodecyl sulfate [SDS]) supplemented with Halt Protease inhibitors (Thermo Fisher Scientific, 
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MA). The cell lysate was sonicated for 5 seconds at 30% Amplitude and quantified using a 
standard Coomassie protein assay (Pierce Biotechnology, IL). The lysate was denatured in 4% 
SDS sample buffer with 10% (v/v) 2-mercaptoethanol, then incubated for 5 minutes at 95˚C. The 
amount of 50 µg of the lysate was electrophoresed though a 10% Protean-TGX gel (BioRad, 
CA) and transferred to nitrocellulose overnight in a buffer containing 0.1% SDS and 10% 
methanol. The membrane was incubated in blocking buffer (5% (w/v) milk in 50 mM TBS with 
0.1% Tween-20 [TBST]), followed by overnight incubation in 1µg/ml Anti-MUC1 (VU-11D1) 
antibody in TBST with 5% (w/v) BSA. The membrane was washed 3 times for a total of 15 
minutes in TBST and then incubated for 1 hour in HRP conjugated secondary antibody. Washes 
were repeated and the bands visualized by soaking the membrane for 3 minutes in SuperSignal 
West Femto Luminol substrate (Thermo Fisher Scientific, MA) followed by standard 
autoradiography. To ensure equal loading, the membrane was stripped by incubating with 
agitation for 1 hour at 50˚C in stripping buffer containing 2% SDS, 0.1 M Tris HCl (pH 6.8) and 
1% (v/v) 2-mercaproethanol. The membrane was washed for 1 hour with continuous fresh 
deionized water and incubated for 1 hour in the blocking buffer. Anti-α-Tubulin monoclonal 
antibody (T6199) (Sigma-Aldrich, MO) was diluted 1:1000 in the fresh blocking buffer and 
incubated for 1 hour. Washings, secondary antibody incubation, and luminol detection were then 
completed as mentioned above. The total intensity of MUC1 bands was quantified by 
densitometry using ImageJ software (NIH, MD) and normalized by the intensity of the α-Tubulin 
band for each cell line.  
4.3.8. Statistical Analysis 
Statistical analysis was carried out using the Microsoft Excel Analysis Tool Pack 
(Redmond, WA). Descriptive statistical parameters (mean and SD) were calculated for the 
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measured OD values. The Student’s t-test was used to assess the statistical significance of the 
difference between the cells with antibody treatments (Ab1+Ab2) and the cells in the presence of 
the secondary antibody (Control Ab2).  
The OD levels of Cell Control and Control Ab1 were at the baseline in all experiments; 
therefore, they were not further considered. A p-value < 0.05 was considered to be statistically 
significant. A total of n=12 experiments for Cell ELISA in live cells and n=10 experiments for 
Cell ELISA in fixed cells were evaluated. All the experiments were done in triplicate. The 
statistical analysis using the data derived from Cell ELISA with fixed cells followed by whole 
cell staining was performed using n=4 experiments for OV2008, n=3 experiments for IMCC3, 
and n= 1 experiment for G26, U87, and U373 cell lines. All the experiments included triplicate 
measurements.  
The results for Cell ELISA in fixed cells were further analyzed to account for differences 
in cell numbers in various wells in which the OD measured at 450 nm was divided by the OD 
measured at 595 nm representing cell numbers ([OD450] / [OD595]). 
4.4. Results  
4.4.1. Optimal Experimental Conditions for Cell ELISA Assay  
4.4.1.1. Cell Density 
The optimal cell seeding density was determined using 0.3 × 104 to 10 × 104 cells/well of 
OV2008 cells in Cell ELISA assay using fixed cells (Figure 4.1). The OD value obtained for the 
secondary antibody (Control Ab2) was subtracted from the OD value obtained for Ab1 +Ab2 to 
account for the nonspecific binding ([OD450]Ab1+Ab2 - [OD450]Control Ab2). A cell density of 3 × 104 
cells/well was selected as the optimum cell concentration as the higher cell densities resulted in 
similar responses. 
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4.4.1.2. Antibody Concentrations  
To determine the binding activity of the primary antibody, various dilutions of VU-11D1 
were used to treat OV2008 cells in Cell ELISA assay using live and fixed cells. The assay was 
performed with 1 g/ml concentration of the secondary antibody. The OD level of the secondary 
antibody (Control Ab2) was subtracted from the OD level of Ab1 +Ab2. The dose response 
curve of the primary antibody (Figure 4.2) indicates concentration-dependent responses in Cell 
ELISA assay using fixed cells. The optimal concentration of the primary antibody was found to 
be 1 g/ml (1:100 dilution).  
A similar study using various concentrations (0.005 to 5 g/ml) of the secondary 
antibody with1 g/ml concentration of the primary antibody was performed (data not shown). 
The concentration of 1 g/ml (1:500 dilution) for the secondary antibody was selected as the 
optimum concentration for the next experiments.  
4.4.1.3. Temperature  
To determine the effect of temperature during cell incubation on the efficiency of 
antibody binding measured as OD, Cell ELISA assay using live OV2008 cells was performed at 
4oC and 37oC incubation temperatures. As seen in Figure 4.3, the OD values were not 
significantly different (p>0.05) when evaluating OV2008 cells incubated at 4oC and 37oC. In 
addition to 1-hour incubation, OV2008 cells were incubated for 2 hours at either 4oC or 37oC 
(data not shown). The results obtained for this time point also indicated no difference in antibody 
binding efficiency for cell incubation at 4oC and 37oC.  
Also, to investigate the possible effect of temperature on the IMCC3 cell loss in Cell 
ELISA assay using live cells, a similar study was performed. It was found that the incubation at 
both 37oC and 4oC resulted in the similar loss of IMCC3 cells. This indicates that the IMCC3 
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cell loss in the Cell ELISA assay using live cells occurred independently from the incubation 
temperature.  
4.4.2.  Cell ELISA using Live Cells 
Cell ELISA assay using live cells was performed using four cell lines: OV2008, IMCC3, 
G26, and U87. The cells were seeded at a density of 3 × 104 cells/well. The primary and 
secondary antibodies were used at the optimal concentrations obtained in section 4.4.1.2.  
Figure 4.4 shows the OD values for the tested cell lines in Cell ELISA assay using live 
cells indicating MUC1 expression. The response in the Control Ab2 relates to the intrinsic 
enzyme activity or nonspecific binding of HRP conjugated secondary antibody to the cell lines. 
The OV2008 cells showed 64% more response in Ab1+Ab2 than Control Ab2 [([OD450]Ab1+Ab2 - 
[OD450]Control Ab2)/ [OD450]Control Ab2 ×100] (p<0.05). Similarly, the G26 cells had 56% more 
response in Ab1+ Ab2 as compared to Control Ab2 (p<0.05). There was no significant 
difference between the OD values for Ab1+Ab2 and Control Ab2 (p>0.05) when IMCC3 and 
U87 cells were evaluated. Therefore, we concluded that although MUC1 expression was detected 
in OV2008 and G26 cell lines using this method, MUC1 expression was not detectable in 
IMCC3 and U87 cell lines. A relatively high cell loss was observed using a light microscope 
during the incubation and washing steps for all the cell lines except for OV2008.  
4.4.3.  Cell ELISA using Fixed Cells  
In an attempt to improve the preservation of cells and minimize cell loss during the 
numerous washing steps, a fixation step with paraformaldehyde was applied in this variant of 
Cell ELISA. A fixation step is considered to be an effective way to inactivate endogenous 
peroxidase activity and, subsequently, to minimize the enzyme background problem that is 
common in eukaryotic cells [14, 20]. Also, to account for the differences in the cell densities and 
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have comparable results, whole-cell staining with Janus Green was used in this Cell ELISA 
method, in which the OD values measured at 490 nm were normalized to the Janus Green 
staining intensity measured at 595 nm ([OD450] / [OD595]). In addition to the cell lines used in 
Cell ELISA assay using live cells, a U373 human glioma cell line was used in this assay.  
Figure 4.5 shows the OD (normalized to cell number) for various cell lines in Cell ELISA 
assay using fixed cells. These data show that fixation with paraformaldehyde did not affect the 
integrity of MUC1 in this assay. The OD indicating expression of MUC1 by OV2008 was 167% 
higher in Ab1+Ab2 treated cells than the Control Ab2 (p<0.05). This difference was 83% and 
101% for IMCC3 and G26 cell lines, respectively. Unlike Cell ELISA assay using live cells, the 
difference between the OD in Ab1+Ab2 and Control Ab2 for IMCC3 cells in this method was 
statistically significant (p<0.05). The U87 and U373 human glioma cell lines did not show 
significant difference (p>0.05) between the OD measured for Ab1+Ab2 and Control Ab2 
indicating that MUC1 expression in these cell lines cannot be evaluated using this technique. 
Therefore, it was concluded that the MUC1 receptor was detected consistently in the two tumor 
cells lines OV2008 and G26. In addition, using this method, MUC1 also was detected in normal 
ovarian epithelial cell control IMCC3. However, two human glioma cell lines U87 and U373 
showed no detectable levels of MUC1. When the levels of MUC1 in epithelial ovarian 
carcinoma OV2008 was compared to the MUC1 levels in the normal ovarian epithelial control 
IMCC3, a statistically significant difference between these two cell lines was found (Figure 4.6). 
In addition, Figure 4.6 shows a comparison between these two types of Cell ELISA assays, using 
live and fixed OV2008 and IMCC3 cells. When the OD value at 450 nm obtained for Control 
Ab2 was subtracted from the OD value obtained for Ab1 +Ab2  ([OD450]Ab1+Ab2 - [OD450]Control 
Ab2, the difference in the expression level of MUC1 between OV2008 and IMCC3 cell lines was 
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found to be statistically significant (p<0.05) in Cell ELISA using fixed cells, but not in Cell 
ELISA using live cells. 
4.4.4. Flow Cytometry 
To validate the developed Cell ELISA assays, flow cytometry analysis was performed on 
OV2008 cells. Analysis of the data obtained from flow cytometry using CFlow Plus software 
showed the expression of MUC1 in OV2008 cells (Figure 4.7). From the representative data, 
42.9% of the cells treated with anti-MUC1 primary antibody and PE-conjugated secondary 
antibody (Ab1+Ab2) and 7.87% of the cells treated with PE-conjugated secondary antibody 
(Control Ab2 PE) were identified as PE-positive, indicating 35% of the OV2008 cells as MUC1-
positive in this experiment and with a similar range of 30% to 45% of MUC1-positive cells in all 
four experiments. 
4.4.5. Western Blot 
Western blot analysis was performed to determine the relative amount of MUC1 protein 
in OV2008 and U87 cell lines and to further validate experiments using Cell ELISA. The Cell 
ELISA demonstrated an attenuated expression of MUC1 in U87 and an increased level of MUC1 
expression in OV2008 cells. Therefore, whole cell lysates were created in an SDS buffer using 
OV2008 and U87 cell lines to provide positive and negative controls, respectively.  
Figure 4.8A shows equal loading of total cell lysate in both gel lanes (OV2008 and U87) 
as seen by immunoblotting using anti-α-Tubulin antibody. MUC1 staining resulted in multiple 
bands ranging in size from approximately 30 to 65 kDa. The most prominent band resolved at 
approximately 55 kDa in OV2008 cells but not U87. An intense band around 60 kDa was 
observed in both cell lines. Densitometry analysis of Western blot bands revealed more than a 
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twofold higher expression level of MUC1 (normalized to α-Tubulin) in OV2008 when compared 
to U87 (Figure 4.8B). 
4.5. Discussion 
Two variants of Cell ELISA using live and fixed cells are described in this study. 
Initially, Cell ELISA assay using live cells was performed due to the previously-reported 
concerns about alteration and/or loss of integrity of cell bound antigens when using fixation [14, 
21]. Normal goat serum was used in the blocking agent to block any non-specific binding of goat 
anti-mouse IgG secondary antibody. As one of the most effective blocking methods, using 
normal serum from the same host species as the labeled secondary antibody prevents non-
specific binding of the labeled IgG antibody. In an effort to optimize the assay, various 
concentrations of the antibodies were examined in the preliminary experiments for OV2008 
cells, and the optimal concentrations of primary and secondary antibody were determined. A 
significant loss of cell monolayer was observed in Cell ELISA assay using live cells for all the 
cell lines (except OV2008), in spite of following a gentle washing protocol [20]. The detachment 
of cells (except OV2008) during the washing steps in this assay resulted in large variations in the 
number of recovered cells. The expression of MUC1 was detected only for the OV2008 and G26 
cell lines in Cell ELISA assay using live cells (as seen in Figure 4.4 and summarized in Table 
4.1). Cell ELISA for live cells could not be used for IMCC3 because of the high cell loss. 
Therefore, a fixation step was added to both improve cell preservation and to reduce the 
background due to endogenous peroxidase activity [14, 20]. The use of a fixation step helped to 
retain a cell monolayer which was confirmed by using whole cell staining with Janus Green at 
end of the assay. Also, visual inspection of the cell monolayer under the light microscope 
supported that a cell monolayer was retained using fixation.  
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Using fixed cells, a significantly higher expression level of MUC1 was detected for the 
OV2008 cell line when compared to IMCC3 normal control. The results obtained for OV2008 
(human ovarian carcinoma cell line) are consistent with the well-documented overexpression of 
MUC1 in almost all human adenocarcinomas (including 90% of breast, ovarian, pancreatic, 
colorectal, lung, prostate, and gastric carcinomas) [22-25].  
In contrast to Cell ELISA assay with live cells, IMCC3 cells showed MUC1 expression 
in Cell ELISA assay with fixed cells, due to the sufficient cell numbers available for evaluation 
and possibly due to the reduced endogenous peroxidase activity.  
Although being known as an epithelial-specific antigen, variable levels of MUC1 have 
been reported to be expressed by many other cancer cells, including astrocytoma, melanoma, and 
neuroblastoma as well as hematologic malignancies (multiple myeloma and some B-cell non-
Hodgkin lymphomas) [12, 26, 27]. The data obtained in this study regarding the relatively low 
level of MUC1 expression by normal epithelial ovarian cells lines, e.g., IMCC3, when compared 
to the MUC1 levels expression by ovarian carcinoma of epithelial origin e.g., OV2008, support 
previously-reported findings by other investigators [23, 28, 29] who used other methodologies 
for MUC1 detection. This also confirms the reliability of the Cell ELISA assay described here as 
a method of choice for the detection of MUC1 expression by normal and tumorous epithelial cell 
lines.  
To further compare findings regarding MUC1 expression using the Cell ELISA method 
developed in this study to findings of other investigators using different methodologies, we 
included additional cell lines such as U87 human glioma cell line reported previously to have no 
detectable levels of MUC1 [30, 31]. Again, we were able to confirm those previous findings, and 
the U87 human glioma cell line served in our studies as a negative control. 
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In addition, we included another human glioma cell line, U373, which has comparable 
characteristics to the U87 human glioma cell line by not exhibiting the typical and expected 
migratory capacity in vivo when implanted intracerebrally, resulting in extended survival times 
[32]. Again, our data regarding MUC1 expression were the same for the U373 human glioma 
cell line as for the U87 glioma, suggesting a possible connection between MUC1 expression and 
invasiveness of tumor cell lines. Our Cell ELISA assay consistently showed that MUC1 level 
was not detectable on these two cell lines providing an additional negative control. 
However, to further test this possible connection between the expression of MUC1 and 
the migratory and invasive characteristics of tumor cell lines, we included the G26 glioma cell 
line, which was shown in our previous study to be highly invasive in vitro and in vivo in the 
orthotopic intracerebral mouse model and expressing markers found in immature progenitor 
cells, which were not found in U87 and U373 glioma [33]. The data from this study showed that 
this highly invasive and migratory G26 glioma cell line expressed MUC1. In light of this finding, 
MUC1 could be considered as another marker of tumor cell invasiveness, but this is a focus of a 
separate and currently ongoing study in our laboratory. 
We concluded that fixation of cells (with paraformaldehyde) in the Cell ELISA technique 
is essential to obtain reliable data. We found that fixation did not interfere with MUC1-antibody 
binding. This finding is consistent with the previous MUC1 quantification studies using flow 
cytometry where a fixation step had been applied [10-12]. In addition, the implementation of 
whole-cell staining with Janus Green in Cell ELISA assay using fixed cells improved the 
accuracy of the assay by allowing for a normalization of the OD data based on cell numbers. 
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To validate the developed Cell ELISA assay as an effective method for quantification of 
MUC1, flow cytometry was performed on OV2008 cells. The percentage of MUC1-positive cells 
determined by flow cytometry correlated with the Cell ELISA results.  
The results of the Cell ELISA assay were validated additionally by Western blotting of 
OV2008 and U87 cell lines. Multiple bands ranging in size from approximately 30 to 65 kDa 
were observed for MUC1 staining. Previous studies with Western blotting of MUC1 have clearly 
demonstrated cleavage of the α- and β-subunits of MUC1 using SDS [34]. The anti-MUC1 
antibody (VU-11D1) was raised against the epitope TSAPDTR, which is found within the 
variable number tandem repeat (VNTR) region on the extracellular side of the protein [35]. 
Therefore, the antibody was raised to detect the extracellular side of the protein. Additionally, 
the extracellular domain of MUC1 can vary significantly in length among different cell lines due 
to the VNTR domain existing between 20 to 125 repeats among different individuals [36]. 
Densitometry demonstrated a greater than two-fold increase in MUC1 expression in OV2008 as 
compared to U87, and this correlates with the results obtained by Cell ELISA. Both flow 
cytometry and Western blotting analyses correlated well with the Cell ELISA data, thus 
providing validation for the results. 
This Cell ELISA assay offers the convenience of testing various samples in multiple 
replicates on a single 96-well plate at once while using a small number of cells and reagents and 
inexpensive equipment.  
The overexpression of MUC1 in certain cancer cells makes it an attractive therapeutic 
target for the design of a drug delivery system based on chitosan, which has been shown to have 
a strong mucoadhesive property [1, 37]. Having a sensitive and reproducible assay to detect the 
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expression of MUC1 in various cancer cells is essential for the further development of a 
previously-published drug delivery system with chitosan hydrogel [38, 39]. 
In summary, the newly-established Cell ELISA technique using fixed cells described in 
this paper can be used as a simple method to quantify the expression of MUC1 antigen on the 
surface of cells of epithelial and neuroectodermal origin in comparison to the normal controls.  
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Figure 4.1 Effect of cell seeding density on the efficiency of antibody binding for OV2008 cells 
in Cell ELISA using fixed cells. The OD level obtained for the secondary antibody (Control 
Ab2) was subtracted from the OD level obtained for Ab1 +Ab2. The data represent the mean of 
duplicate samples. 
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Figure 4.2 Titration of VU-11D1 antibody, OV2008 cells were used at the density of 3 × 104 
cells/well in Cell ELISA using fixed cells. The OD level obtained for the secondary antibody 
(Control Ab2) was subtracted from the OD level obtained for Ab1 +Ab2. The data represent the 
mean of duplicate samples. 
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Figure 4.3 Effect of incubation temperature on the efficiency of antibody binding for OV2008 
cells in Cell ELISA using live cells. The OD level obtained for the secondary antibody (Control 
Ab2) was subtracted from the OD level obtained for Ab1 +Ab2. The temperature had no 
statistically significant effect on the antibody binding efficiency measured as OD. The data 
represent n=2 experiments with triplicate samples. 
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Figure 4.4 Cell ELISA assay using live OV2008, IMCC3, G26 and U87 cell lines. The data 
represent the mean of OD values for n=3 experiments with triplicate samples for OV2008 and 
IMCC3 cells and n=1 experiment for G26 and U87 cells with triplicate samples. The statistical 
significance between Ab1+Ab2 and Control Ab2 was analyzed using Student’s t-test: *, p<0.05. 
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Figure 4.5 Cell ELISA using fixed cells (normalized by cell number) for OV2008, IMCC3, G26, 
U87, and U373 cell lines. The data represent the mean of OD values for n=4 experiments for 
OV2008, n=3 experiments for IMCC3, and n=1 experiment for G26, U87, and U373 cell lines all 
with triplicate samples. The statistical significance between Ab1+Ab2 and Control Ab2 was 
analyzed using Student’s t-test: *, p<0.05. 
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Figure 4.6 Cell ELISA using fixed and live OV2008 and IMCC3 cells. The OD value at 450 nm 
obtained for Control Ab2 was subtracted from the OD value at 450 nm obtained for Ab1 +Ab2. 
The data represent n=3 experiments for live IMCC3 and OV2008 cells, n=3 experiments for 
fixed IMCC3 cells, and n=4 experiments for fixed OV2008 cells all with triplicate samples. The 
statistical significance between IMCC3 and OV2008 cell lines was analyzed using Student’s t-
test: *, p<0.05. 
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Figure 4.7 Flow cytometric evaluation of MUC1 expression in OV2008 cells. The 
superimposed peaks in the histogram represent Ab1+Ab2 (cells treated with anti-MUC1 
antibody and PE conjugated secondary antibody) (filled black) and Control Ab2 PE (cells 
treated with PE conjugated secondary antibody) (dashed gray line). The histogram is a 
representative of four independent experiments. 
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Figure 4.8 Evaluation of MUC1 expression in OV2008 and U87 cell lines using Western blot. 
A) Cell lysates were harvested and used at 50 g. -Tubulin was used as a sample loading 
control. B) Quantification of the MUC1 expression was performed with densitometric analysis 
by ImageJ software and normalized to -Tubulin.  
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Table 4.1 Summary data for Cell ELISA in live cells and Cell ELISA in fixed cells 
Cell line Cell ELISA in live cellsa Cell ELISA in fixed cellsb 
OV2008 64% 167% 
IMCC3 NS 83% 
G26 56% 101% 
U87 NS NS 
U373 ND  NS 
NS = No significant difference between Ab1+Ab2 and Control Ab2 was found. 
ND = Not determined. 
 
a  ሾ۽۲૝૞૙ሿۯ܊૚శۯ܊૛ିሾ۽۲૝૞૙ሿ۱ܗܖܜܚܗܔ	ۯ܊૛ሾ۽۲૝૞૙ሿ۱ܗܖܜܚܗܔ	ۯ܊૛ ൈ ૚૙૙ 
b   ሾ۽۲૝૞૙/۽۲૞ૢ૞ሿۯ܊૚శۯ܊૛ି	ሾ۽۲૝૞૙/۽۲૞ૢ૞ሿ۱ܗܖܜܚܗܔ	ۯ܊૛
ሾ۽۲૝૞૙/۽۲૞ૢ૞ሿ۱ܗܖܜܚܗܔ	ۯ܊૛ ൈ ૚૙૙ 
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CHAPTER 5: ATR-FTIR ANALYSIS OF SPECTRAL AND BIOCHEMICAL CHANGES 
IN GLIOMA CELLS INDUCED BY CHLOROTOXIN 
 
5.1. Abstract 
Chlorotoxin (CTX) is a small peptide with unique targeting properties towards gliomas 
and other tumors of the neuroectodermal origin. Despite being investigated in many in vivo and 
in vitro targeted drug delivery and imaging studies, the mechanism of interaction between CTX 
and tumor cells has not been well understood. This study presents a new approach in monitoring 
the biochemical and biophysical changes in glioma cells after being exposed to CTX using 
Attenuated Total Reflection Fourier Transform Infra-Red (ATR-FTIR) spectroscopy. In the first 
part, we characterized the signature spectra of CTX and U87 cells. Next, we evaluated the 
differences in biochemical compositions of the spectra of the glioma cells treated with and 
without CTX over different incubation time periods. Our results indicated biochemical changes 
in U87 cells at different stages of incubation with CTX, with the most notable changes occurring 
after 30 min of incubation. Detailed comparisons of the spectra of the U87 cells treated with and 
without CTX for 30 min revealed distinct changes and shifts in the band frequencies associated 
with proteins and lipids. In particular, a downshift of the band assigned to CH2 scissoring of lipid 
membranes from 1454 cm-1 to 1448 cm-1 followed by an appearance of a new shoulder at 
wavenumber of 1465 cm-1 revealed conformational changes in hydrocarbon chain packing in 
lipid bilayers of U87 cells due to CTX. Other frequency shifts indicated additional changes in 
conformation and orientation of lipids and proteins in U87 cells exposed to CTX.  
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5.2. Introduction 
Chlorotoxin (CTX) is a 36-amino acid peptide derived from the venom of the scorpion 
Leirius quinquestriatus that preferentially binds to tumor cells of neuroectodermal origin, such as 
glioma, but not to normal non-transformed cells [1-3]. 
Several studies have demonstrated its use as an imaging and targeting agent for drug and 
radioisotope delivery [4-7]. However, the mechanism of interaction of CTX with cancer cells has 
not been well understood, and it needs to be further evaluated to optimize its use as a targeting 
compound for cancer cells. 
 Attenuated Total Reflection Fourier Transform Infra-Red (ATR-FTIR) spectroscopy is a 
well-established analytical method for the detection of molecular and structural changes in a 
wide range of chemical and biological samples [8]. As a label-free technique, it has been widely 
used for various exploratory and diagnostic investigations [9, 10]. A well-studied example is 
investigating the differences between the spectra of cancerous and non-cancerous cells and 
tissues [11-15].  
In this study, we used ATR-FTIR spectroscopy to analyze the spectral and biochemical 
changes induced in U87, a glioma cell line, exposed to CTX at different incubation times. First, 
we characterized the signature spectra of CTX and U87 cells by assigning and evaluating the 
infrared absorption bands and their second derivatives.  
Next, we analyzed the differences in biochemical compositions of the spectra of the 
glioma cells incubated with and without CTX by calculating the ratios of the areas of the bands 
corresponding to proteins, lipids, nucleic acids, and carbohydrates. Detailed comparisons of the 
spectral changes and band shifts also were performed, and possible mechanisms for the observed 
changes were further discussed.   
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5.3. Materials and Methods 
5.3.1. Cell Line 
U87, a human glioblastoma astrocytoma cell line (American Type Culture Collection) 
was used in this study. Cells were cultured in Minimum Essential Medium with Earle’s Balanced 
Salts (MEM/EBSS; Hyclone, UT) supplemented with 10% Fetal Bovine Serum (FBS) and 2 mM 
L-glutamine, penicillin, and streptomycin. Cells were grown in 25 cm2 culture flasks (Corning, 
NY) and incubated at 37oC with 5% CO2. 
5.3.2.  Cell Treatment with CTX  
Cells were detached from adherent cultures using trypsinization (0.05% Trypsin/0.53mM 
EDTA; Corning, NY) and resuspended in the growth medium. After adjusting the cell density to 
5×105 cells/ml, 250 l of the cell suspension (1.25×105 cells) was placed in micro-centrifuge 
tubes. Cells received 25 l of CTX (Iris Biotech, Germany) at a concentration of 10 M 
(U87+CTX) or 25 l of the culture medium (U87) and incubated for incremental time periods 
ranging from 15 min to 24 h at 37oC in 5% CO2. Following the incubation, cells were washed 3 
times with 0.9% NaCl solution (Sigma-Aldrich, MO) and centrifuged at 400 g for 5 min to 
remove the culture medium and the unbound CTX.  Cells were then resuspended in 0.9% NaCl 
solution and adjusted to a density of 5×105 cells/ml.  
5.3.3. ATR-FTIR Spectroscopy 
The ATR-FTIR spectra were obtained using a Nicolet 6700 spectrometer (Thermo 
Scientific, WI). A total of 100 l of the prepared cell suspensions was introduced onto a 45o 
ZnSe flat crystal (Thermo Scientific, WI) and allowed to air dry for 1 hr. To remove any excess 
water, the formed films were exposed to an ultrapure nitrogen flux before collecting the spectra. 
The spectra in the 4000-400 cm-1 region were collected using 300 scans at a spectral resolution of 
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4 cm-1. It should be noted that both U87+CTX and U87 cells were washed after incubation and 
before taking the spectra; therefore, the interference of unbound CTX was eliminated from the 
spectra.   
5.3.4. Data Analysis  
The data analysis was performed using OMNIC software (Thermo Scientific, WI). To 
ensure appropriate comparison between different samples, all the spectra were baseline corrected 
and normalized to amide I band at 1655 cm-1. The complexity of the cell structure due to the 
presence of proteins, lipids, carbohydrates, and nucleic acids results in broad and superimposed 
bands in several spectral regions. As a resolution enhancement technique, the second derivative 
of each processed spectrum was calculated using Savitsky–Golay derivative function to resolve 
broad and overlapping bands into individual bands and eliminate possible artifacts. The areas 
under specific peaks in the absorbance spectrum were measured using OMNIC software. The 
subregion for each peak was selected based on the range of the peak resolved using the 
secondary derivative spectrum. This analysis was performed in triplicate. Statistical analysis was 
carried out using the Microsoft Excel Analysis Tool Pack. The data presented as descriptive 
statistical parameters (mean and SD). The Student’s t-test was used to assess the statistical 
significance of the differences between U87 cells incubated in the absence and presence of 
chlorotoxin. **p < 0.01 and *p < 0.05 were considered to be statistically significant.  
5.4. Results and Discussion 
5.4.1. Vibrational Assignments 
5.4.1.1. Chlorotoxin (CTX) 
The absorption and the second derivative spectra of CTX are shown in Figure 5.1a, b. 
The characteristic frequency values and detailed assignments of the major bands are listed in 
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Table 5.1. The most prominent bands were observed at 1645 cm-1 and 1545 cm-1 assigned to 
amide I and amide II -helical structures, respectively. The band at 1516 cm-1 was associated 
with (C-C) and (C-H) of Tyrosine ring. Similarly, the 1446 cm-1 peak was assigned to (CH2) 
of Tyrosine and Phenylalanine amino acid side chains present in CTX. The peaks at 1408 cm-1 
and 1388 cm-1 were assigned to (C-N) of Glutamine and Methionine and w(CH2) of Tyrosine, 
respectively. The strong amide I and amide II bands observed in the spectrum of CTX were both 
associated with the -helical structure. This was in accordance with the Nuclear Magnetic 
Resonance (NMR) studies where the solution structure of CTX has been shown to be mainly an 
-helix packed against a small -sheet and cross-linked by three disulfide bonds [16].   
5.4.1.2. U87 Cells  
The absorption and the second derivative spectrum of U87 cells are shown in Figure 
5.2a–d. The 3000–2820 cm-1 spectral region (Figure 5.2a, c) includes the bands that are 
associated with symmetric and antisymmetric stretching vibrations of CH3 and CH2 groups, 
mainly from lipids. Whereas the strong amide I band at 1655 cm-1 (Figure 5.2b, d) represents -
helical structure of proteins, the band at 1635 cm-1 is associated with -sheet secondary structure 
of proteins in U87 cells. The shoulder at 1684 cm-1 also corresponds to antiparallel -sheet 
structure of proteins [17]. The band at 1543 cm-1 was assigned to amide II. The band at 1739 cm-
1 is primarily associated with stretching vibrations of lipid ester carbonyls [18, 19].  A list of 
detailed characteristics of all the major bands in the spectra of U87 cells is given in Table 5.2. 
5.4.2. Analysis of the Integrated Area Ratios  
Calculating the ratios of the areas of the bands corresponding to proteins, lipids, nucleic 
acids, and carbohydrates is one of the Feature Extraction (FE) techniques that has been used for 
the analysis of the spectra of the biological materials [20].  To monitor the biochemical changes 
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in U87 cells induced by CTX at different incubation time points, the ratios of the integrated areas 
of the bands at 1740 cm-1, amide II (1543 cm-1), 1080 cm-1, and 1050 cm-1 corresponding to 
lipids, proteins, nucleic acids, and carbohydrates were calculated and compared to those of U87 
cells without CTX treatment.  
Figure 5.3 shows the ratio of the areas under amide II and 1742 cm-1 bands corresponding 
to protein and lipid, respectively [21]. The most significant change occurred for U87 cells after 
30 min of incubation with CTX, where the protein-to-lipid ratio had a 65% increase (**p < 0.01) 
compared to U87 cells without CTX treatment. Similarly, 21% and 33% increases in protein-to-
lipid ratio (**p < 0.01) were found for U87 cells incubated with CTX (U87+CTX) for 15 min and 
1 h compared to U87 cells. This increase implies the cellular uptake of CTX in U87 cells 
incubated with CTX. Whereas 2 h of incubation resulted in an 18% increase in the ratio (*p < 
0.05) for U87+CTX cells compared to U87, no significant difference of this ratio was found 
between U87 and U87+CTX after 3 h and 24 h of incubation.  
The changes in amide II: 1080 cm-1 area ratio (representing protein-to-nucleic acid ratio) 
in U87 and U87+CTX cells at different incubation times are shown in Figure 5.4. A 33% 
increase (*p < 0.05) for this ratio occurred for U87 cells incubated with CTX for 30 min 
compared to U87 cells. No significant difference of this ratio was found between U87 and 
U87+CTX for other incubation time points.  
The ratios of the areas under amide II and 1050 cm-1 bands corresponding to protein and 
carbohydrate, respectively, are shown in Figure 5.5.  A 70% and 41% increase (**p < 0.01)  for 
this ratio occurred for U87 cells incubated with CTX for 1 h and 30 min compared to U87 cells. 
Similarly, 22% and 27% increase in protein-to-carbohydrate ratio (*p < 0.05) were found for U87 
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cells incubated with CTX (U87+CTX) for 2 h and 24 h compared to U87 cells. No significant 
difference of this ratio was found between U87 and U87+CTX for 3 h.  
As can be seen in Figures. 5.3, 5.4, and 5.5, significant differences between U87+CTX 
and U87 cells were found for all the measured ratios after 30 min of incubation. Therefore, the 
spectra of this time point were selected for detailed evaluation of the spectral changes in the 
following section.  
5.4.3. Spectral Changes for U87 Cells after 30 min Treatment with CTX 
Detailed comparisons between the spectra of U87 and U87+CTX cells were performed in 
the following three spectral regions. 
5.4.3.1. 1760–1480 cm-1 
Figure 5.6 shows the absorption and second derivative spectra of U87 cells incubated 
with and without CTX for 30 min in the frequency region of 1760–1480 cm-1. Several spectral 
shifts occurred for U87+CTX peaks compared to those of U87 cells in this region, which can be 
easily traced in the second derivative spectra shown in Figure 5.6. It can be seen that the peak at 
1739 cm-1 associated with (C=O) of ester groups, primarily from lipids and fatty acids in U87 
cells, shifted to 1744 cm-1 for U87+CTX. Also, the shoulder at 1718 cm-1 diminished and almost 
disappeared for U87+CTX cells.  
The bands around 1740 and 1730 cm-1 have been reported to reflect the stretching 
vibrations of non-hydrogen bonded and hydrogen bonded lipid ester carbonyls, respectively [17, 
18]. They have been used to probe the changes in physical packing of lipid bilayers where tightly 
packed lipids show a lower portion of hydrogen-bonded carbonyls due to the lower water 
penetration into the interfacial region of the bilayer. Therefore, the observed upshift of the band 
at 1739 to 1744 cm-1 is indicative of an increase in the amount of non-hydrogen bonded lipid 
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ester carbonyls in the membrane bilayers of U87+CTX cells compared to U87 cells, suggesting 
that CTX induces changes in physical packing of U87 cell membranes. This is in agreement with 
previous studies in which the incorporation of a protein into lipid bilayer membranes resulted in 
an increase in the percentage of non-hydrogen bonded lipid ester carbonyls [18, 22].  
Along with these changes, other shifts in this region were observed for amide I peaks, 
including upshifts of the bands at 1684 cm-1  and 1653 cm-1  for U87 cells to 1688 cm-1 and 1656 
cm-1 for U87+CTX cells, respectively. These upshifts are indicative of conformational changes 
[18, 22]. Also, the shoulder at 1635 cm-1 assigned to amide I, -sheet secondary structure 
diminished and almost disappeared for U87+CTX cells. This further confirms that secondary 
structure of proteins was affected by CTX. As can be seen in Figure 5.6, the amide II band had a 
6 cm-1 upshift in the spectra of U87+CTX cells compared to U87 cells. As shown in several 
studies, the frequency changes in amide bands correlate with the strength alterations of the 
hydrogen bonds [22-24]. While an upshift represents weakening of hydrogen bonds in stretching 
vibrations, it indicates stronger hydrogen bonds for bending vibrations [23]. It has been shown 
that the shifts of amide II band induced by hydrogen bonding derive predominantly from N-H 
bending [25]. Therefore, the observed upshift of amide II band in the spectra of U87+CTX 
compared to U87 cells indicates an increase in N-H hydrogen bonding within transmembrane 
proteins. Other changes included two shifts of the peaks at frequencies of 1513 cm-1 and 1492 
cm-1 for U87 cells to 1516 cm-1 and 1496 cm-1 for U87+CTX cells, respectively. All the changes 
are summarized in Table 5.3.  
5.4.3.2. 1480–1280 cm-1 
Comparative representations of the absorption and second derivative spectra of U87 cells 
incubated with and without CTX for 30 min in the frequency region of 1480–1280 cm-1 are 
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shown in Figure 5.7. A new shoulder appeared at 1465 cm-1 for U87+CTX cells, which was 
assigned to CH2 scissoring of lipids.  
The peak at 1454 cm-1 assigned to asymmetric CH2 and CH3 in plane bending vibrations 
in lipids for U87 cells downshifted to 1448 cm-1 for U87+CTX cells. The shifts in CH2 scissoring 
bands have been reported to associate with the changes in conformational orders and chain 
packing of lipid molecules [22, 26]. In particular, a downshift of the CH2 scissoring bands has 
been associated with transitions from typical highly-ordered orthorhombic phases to a metastable 
hexagonal phase [22, 26]. Therefore, the observed downshift along with the appearance of the 
shoulder at 1465 cm-1 indicates the changes in the conformational ordering and lateral packing of 
the hydrocarbon chains of the lipid molecules in U87 cell membranes induced by CTX. Similar 
changes also were observed for U87+CTX cells after 15 min and 1 h of incubation (data not 
shown). 
A large upshift of 9 cm-1 was observed for the 1341 cm-1 peak of U87 cells assigned to 
CH2 wagging of phospholipid, fatty acid, triglyceride, and amino acid side chains, where it 
shifted to 1350 cm-1 for U87+CTX cells. The CH2 wagging modes have been used to monitor the 
conformational sequences and trans-gauche isomerization of acyl chain in lipid bilayers [26, 27]. 
While the wagging mode at 1341 cm-1 reflects an end-gauche conformation, the band at 1354 
cm-1 corresponds to double-gauche conformations [26]. Thus, the observed upshift of CH2 
wagging band from 1341 to 1350 cm-1 clearly indicates a change in the conformational orders of 
acyl chains in lipid bilayers.  
In addition, an increase in the number of gauche conformers has been associated with an 
increase in disordering of the lipid bilayers [26, 28], suggesting that the upshift of CH2 wagging 
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band is indicative of an increase in conformational disorders of acyl chains in lipid bilayers of 
U87 cells due to CTX.  
5.4.3.3. 1280–880 cm-1 
The absorption and second derivative spectra of U87 cells incubated with and without 
CTX for 30 min in the frequency region of 1280–880 cm-1 are shown in Figure 5.8. This region 
includes the absorbance of infrared mainly due to the presence of phosphates, carbohydrates, and 
nucleic acids. Two major shifts were observed for U87+CTX cells compared to U87 cells after 
30 min of incubation in this region. The 1051 cm-1 peak for U87 cells assigned to stretching 
vibrations of COH group in carbohydrates (polysaccharides or glycogen) had a 4 cm-1 downshift 
to 1047 cm-1 for U87+CTX cells. Also, the 916 cm-1 peak assigned to ribose ring vibration of 
RNA for U87 cells upshifted to 922 cm-1 for U87+CTX cells. All the spectral changes for U87 
cells after 30 min of treatment with CTX are summarized in Table 5.3.  
5.5. Conclusions 
We used ATR-FTIR spectroscopy to evaluate the biochemical changes in U87 glioma 
cells in response to incubation with CTX at different time intervals. The analysis of the 
integrated area ratios of the bands corresponding to major biochemical components (protein-to-
lipid, protein-to-carbohydrate and protein-to-nucleic acid) indicated that the most significant 
changes between U87 and U87+CTX cells occurred at the incubation period of 30 min.  
Comparisons of the different regions of the spectra for U87 and U87+CTX cells 
incubated for 30 min revealed distinct changes and shifts in the band frequencies. The band at 
1739 cm-1 associated with (C=O) of lipids shifted to 1744 cm-1, indicating an increase in the 
percentage of non-hydrogen bonded lipid ester carbonyls in U87+CTX cells compared to U87 
cells. The shifts of the amide I bands associated with the conformational changes in 
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transmembrane proteins of U87+CTX cells compared to U87 cells. The upshift of the amide II 
band further confirmed the conformational changes and indicated an increase in N-H hydrogen 
bonding within transmembrane proteins.  
The most significant changes occurred for the bands associated with CH2 deformations, 
indicating lipid fatty acyl chain disorders. First, the 6 cm-1 downshift of the CH2 scissoring band 
at 1454 cm-1 along with the appearance of the shoulder at 1465 cm-1 indicated conformational 
alteration in ordering and lateral packing of the hydrocarbon chains of the lipid molecules, 
suggesting transitions of the lipid chains from highly-ordered orthorhombic phases to a 
metastable hexagonal phase. This was further supported by 9 cm-1 upshift of the band at 1341 
cm-1 associated with CH2 wagging, which indicated an increase in the number of gauche 
conformers, implying an increase in conformational disorders of acyl chains in lipid bilayers of 
U87+CTX cells compared to U87 cells due to CTX. These findings are particularly interesting, 
as they suggest CTX introduces disorders in lipid acyl chains of the lipids in U87+CTX cell 
membranes.  
Our results indicate that ATR-FTIR can be used to monitor the biochemical changes 
induced in glioma cells by CTX. Also, we were able to detect important conformational and 
structural changes in glioma cells due to CTX.  
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Figure 5.1 Absorption (a) and corresponding second derivative (b) spectra of CTX in frequency 
region of 1800–900 cm-1 
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Table 5.1 Frequencies and assignments of major absorption peaks in ATR-FTIR spectra of CTX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Wavenumber (cm-1) Assignment Major Contribution 
 (C=O) Aspartic acid [29] 
 (C=O) Glutamine [29] 
 (C=O) Amide I, -helix [30, 31] 
 (NH2) 
(C-C) ring
Glutamine [29] 
Phenylalanine, Tyrosine 
 (N-H) + (C-N) Amide II 
 (C-C) ring +  
(C-H) 
Tyrosine [17, 29] 
1446 (CH2)  Phenylalanine, Tyrosine [29, 
31, 32] 
Glutamine  
Proline  
1409 (C-N) Glutamine [17, 29, 32]  
Methionine  
1387 w(CH2)  Tyrosine [29] 
1340 (CH)  
t(CH2)  
Cysteine [29, 32] 
Proline 
1313 (CH2)  Glutamine [29, 32] 
1231 ν(CO)  Tyrosine [29, 33] 
1175 (CH2) + 
(COH)  
Tyrosine [29, 32] 
1155 ν(C-O)  Threonine [29] 
1109 (CH2)  Histidine [29] 
 (C=C) ring Histidine [29] 
923  ring  (C-C)  Histidine [29] 
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Figure 5.2 Absorption and second derivative spectra of U87 cells in frequency region of 3000–
2820 cm-1 (a, c) and 1800–850 cm-1 (b, d)  
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Table 5.2 Band assignments of major peaks in IR spectra of U87 cells in 2980–900 cm-1 region 
Wavenumber (cm-1) Assignment Major Contribution 
2960  as(CH3) Saturated fatty acids 
2922 as(CH2) Saturated fatty acids
2873 s(CH3) Saturated fatty acids
2851 s(CH2) Saturated fatty acids
1739 (C=O)  Phospholipids – cholesterol ester 
1684 Amide I, antiparallel -
sheet
Protein 
1655 Amide I, -helix Protein 
1635 Amide I,  -sheet Protein 
1584 as(COO-) 
(C-C) tyrosine  
Protein [29, 33] 
1543  Amide II Protein 
1455 as(CH2), as(CH3)  Mainly lipids, with small 
contribution from proteins [11, 12, 
19, 34, 35] 
1400 s(C=O) of COO- 
s(CH2), s(CH3) 
Lipids and proteins [11, 35] 
1342 CH2 wagging Phospholipid, fatty acid, amino 
acid side chains [13, 19] 
1312 (C-N) Proteins [36] 
1237 as(PO2-)  
 
Mainly nucleic acids, with small 
contribution from phospholipids 
1170 as(C-O) CO-O-C ester 
bonds 
Phospholipids  – cholesterol ester 
1150 (C-O), (COH)  Carbohydrates
1120  (C-O) Ribose ring – RNA [19, 37] 
1083 s(PO2-)   Nucleic acids, weak glycogen 
1041   (COH)  Polysaccharides, glycogen [11, 19]
992 (C-O), (C-C)  
s(PO4=)   
Ribose – RNA [38] 
RNA [11] 
966  (C-O), (C-C)  
s(PO4=)   
Deoxyribose – DNA [38] 
Phosphorylated proteins and 
nucleic acids [11] 
 ν(COP)  Phosphorylated protein [39] 
Ribose ring: RNA [19, 40] 
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Figure 5.3 Comparisons of amide II/ 1742 cm-1 area ratios for U87 cells with and without CTX 
treatment at different incubation time points. Data represent mean ± SD for n=3 measurements. 
Statistical significance between U87 and U87+CTX analyzed using Student’s t-test: **p<0.01 
and *p<0.05 
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Figure 5.4 Comparisons of amide II/ 1080 cm-1 area ratios for U87 cells with and without CTX 
treatment at different incubation time points. Data represent mean ± SD for n=3 measurements. 
Statistical significance between U87 and U87+CTX analyzed using Student’s t-test: *p<0.05 
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Figure 5.5 Comparisons of amide II/ 1050 cm-1 area ratios for U87 cells with and without CTX 
treatment at different incubation time points. Data represent mean ± SD for n=3 measurements. 
Statistical significance between U87 and U87+CTX analyzed using Student’s t-test: **p<0.01 
and *p<0.05 
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Figure 5.6 Absorption and second derivative spectra of U87 cells incubated with and without 
CTX for 30 min in frequency region of 1760–1480 cm-1 
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Figure 5.7 Absorption and second derivative spectra of U87 cells incubated with and without 
CTX for 30 min in frequency region of 1480–1280 cm-1. The spectral differences between U87 
and U87+CTX were found mainly for the bands associated with CH2 deformations indicating 
lipid fatty acyl chain disorders 
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Figure 5.8 Absorption and second derivative spectra of U87 cells incubated with and without 
CTX for 30 min in frequency region of 1280–880 cm-1  
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Table 5.3 Summary of changes observed in ATR-FTIR spectra of U87 cells incubated with and 
without CTX for 30 min 
 
   
Wavenumber (cm-1) Change Assignment Major Contribution 
U87 U87+CTX 
1739 1744 +5 shift (C=O) Phospholipids – cholesterol ester 
1684 1688 +4 shift   
1653 1656 +3 shift Amide I, -helix Protein
1635  disappeared Amide I, -sheet Protein
1542 1548 +6 shift Amide II, -helix Protein
1513 1516 +3 shift   
1492 1496 +4 shift   
 1465 appeared   
1454 1448 -6 shift as(CH2), as(CH3) Mainly lipids, with small 
contribution from proteins [11, 12, 
19, 34, 35] 
1440  disappeared   
1398 1404 +6 shift s(C=O) of COO- 
s(CH2), s(CH3) 
Lipids 
1341 1350 +9 shift CH2 wagging Phospholipid, fatty acid, 
triglyceride, amino acid side 
chains [19] 
1191 1195 +4 shift  
1051 1047 -4 shift (C-O), (C-O) Polysaccharides , glycogen 
916 922 +6 shift ν(COP) Phosphorylated protein [39] 
Ribose ring – RNA [19, 40] 
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CHAPTER 6: SUMMARY 
 
This study reports a development of a localized and targeted drug delivery system using 
chlorotoxin (CTX) assisted thermosensitive niosome-chitosan hydrogel complexes for cancer 
treatment. With the controlled, sustained and targeted delivery features, this system represents a 
novel approach in cancer therapy.  
Release rate studies indicated that embedding niosomes in chitosan hydrogel significantly 
extends the release rates. Embedding CTX along with niosomes in chitosan hydrogel resulted in 
slightly more extended release rates as compared to the release rates from niosomes alone in 
chitosan hydrogel. Attachment of CTX to the surface of niosomes shown by TEM imaging 
improved the stability of niosomes resulting in extended release rates. ATR-FTIR studies also 
confirmed the interaction of CTX with niosomes.  
Thermosensitive chitosan hydrogels containing Paclitaxel (PTX)-loaded niosomes with 
various amount of crosslinker in their formulations (L-Ch, M-Ch and H-Ch) were also prepared. 
The incorporation of PTX-niosomes in chitosan hydrogels resulted in prolonged release profiles 
which lasted for more than 40 days in a pH-dependent manner. While L-Ch and M-Ch hydrogels 
indicated similar PTX release profiles, relatively slower release rates (around 10%) were found 
for H-Ch hydrogels. The release mechanism was identified as anomalous transport (a 
combination of diffusion-controlled and swelling-controlled release) for L-Ch hydrogels when 
incubated in PBS with pH 6.3. Major changes in swelling behavior were observed for L-Ch and 
M-Ch chitosan hydrogels with small physiologically relevant pH changes.  
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Having a sensitive and reproducible assay to detect the expression of MUC1 in various 
cancer cells is essential for further development of the drug delivery systems using chitosan 
hydrogel which have been shown to have a strong mucoadhesive property. Therefore, two 
variants of Cell ELISA assays using live and fixed cells were developed in this study. It was 
found that the Cell ELISA in live cells was not sensitive enough to detect a difference in MUC1 
levels between the normal cells and tumor cells. However, we found that Cell ELISA in fixed 
cells followed by whole cell staining was a dependable method of MUC1 level detection in the 
normal and tumor cells showing significantly higher levels of MUC1 receptor in the tumor cells 
when compared to the normal controls. Both flow cytometry and Western blotting analyses 
correlated well with the Cell ELISA data and provided validation of the results. 
ATR-FTIR spectroscopy was used to evaluate the biochemical changes in U87 glioma 
cells in response to incubation with CTX at different time intervals. The analysis of the 
integrated area ratios of the bands corresponding to major biochemical components indicated that 
the most significant changes between U87 and U87+CTX cells occurred at the incubation period 
of 30 min. Comparisons of the different regions of the spectra for U87 and U87+CTX cells 
incubated for 30 min revealed distinct changes and shifts in the band frequencies. The most 
significant changes occurred for the bands associated with CH2 deformations, indicating lipid 
fatty acyl chain disorders. First, the 6 cm-1 downshift of the CH2 scissoring band at 1454 cm-1 
indicated conformational alteration in ordering and lateral packing of the hydrocarbon chains of 
the lipid molecules, suggesting transitions of the lipid chains from highly-ordered orthorhombic 
phases to a metastable hexagonal phase. This was further supported by 9 cm-1 upshift of the band 
at 1341 cm-1 associated with CH2 wagging, which indicated an increase in the number of gauche 
conformers, implying an increase in conformational disorders of acyl chains in lipid bilayers of 
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U87+CTX cells compared to U87 cells due to CTX. These findings are particularly interesting, 
as they suggest CTX introduces disorders in lipid acyl chains of the lipids in U87+CTX cell 
membranes. They also indicate that by understanding the interactions between CTX and glioma 
cells, we can achieve the optimized design of CTX assisted drug delivery systems for targeting 
gliomas. 
Together these findings are encouraging as they indicate the developed drug delivery 
system in this study with the distinct tumor targeting features and extended release profiles 
would improve the specific and efficient delivery of anticancer drugs to tumor cells without 
affecting normal cells. 
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